Therapeutic amides

ABSTRACT

The invention provides compounds of the formula: 
                         
wherein A, X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions comprising a compound of the above formula or a salt thereof, intermediates useful for preparing a compound of the above formula, and therapeutic methods comprising administering a compound of the above formula or a salt thereof to a mammal in need thereof.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. Provisional PatentApplication No. 60/393,858, filed, Jul. 3, 2002, which is incorporatedherein by reference.

GOVERNMENT FUNDING

The invention described herein was made in part with government supportunder NCI-NIH Grant Number CA82341 awarded by the National CancerInstitute. The United States Government has certain rights in theinvention.

BACKGROUND OF THE INVENTION

U.S. Pat. Nos. 5,364,831, and 6,197,728, disclose herbicidal compoundsof the formula:

wherein X represents a halogen atom; R includes —C(═O)R¹ where R¹represents various substituted alkoxy radicals, —SR³ radicals, and —NHR⁴radicals where R⁴ is a C₁₋₄ alkoxycarbonylalkyl, hydroxy alkyl, phenyl,C₁₋₄ alkoxy alkyl or di C₁₋₄ alkyl amino groups.

U.S. Pat. No. 4,629,493, discloses herbicidal compounds of the formula:

wherein A is —CH— or —N—; X is a halogen; n is 0, 1, or 2; R¹ ishydrogen or a lower alkyl group; and R² is —OH, —Oalkyl, —OM (inorganicor organic salt), —NR³R⁴ where R³ and R⁴ respectively represent ahydrogen atom or a lower alkyl group. One of these compounds iscurrently sold commercially for the control of annual and perennialgrass weeds in broadleaf crops. This compound has the following formula:

Corbett et. al., Investigational New Drugs, 16, 129–139 (1998),evaluated a series of quinoxaline compounds for activity against solidtumors in mice. The following compound

(herein after referred to as XK469) was reported to have broad activityagainst transplantable mouse tumors. The compound was also reported tohave a relatively low potency, and to produce several undesirable sideeffects, including in vivo toxicity, e.g., paralytic ileus,GI-epithelial damage, marrow toxicity, neuromuscular toxicity, andweight loss.

Hazeldine et al., J. Med. Chem., 2001, 44, 1758–1776, discloseanti-tumor compounds of the formula:

wherein, for example, W can be H or Cl; X can be H, Cl, F, or NO₂; Y canbe H, F, Cl, Br, I, methoxy or —N₃; Z can be H, Cl, or methoxy; and Rcan be OH, alkoxy, or NR′R″, where R′ and R″ are H, methyl, NH₂ or OH,see Table 5 therein.

Hazeldine et al., J. Med. Chem., 2002, 45, 3130, disclose bioisostereand cogener compounds of anti-tumor compound (XK469).

provisional application U.S. Ser. No. 60/309,144, filed Jul. 7, 2001,now PCT application PCT/US02/24442, entitled “Anti-tumor Agents”discloses a compound of the formula:

wherein Y is F, Cl, Br, methyl, or methoxy; or a pharmaceuticallyacceptable salt thereof.

There is currently a need for additional anti-tumor agents.

SUMMARY OF THE INVENTION

The present invention provides compounds that are effective anti-tumoragents. Accordingly, compounds of the invention are of the formula (I):

wherein

A is CH or N;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or (C₁–C₇)alkoxy; and

Z is an amino acid, or heterocycle;

or a pharmaceutically acceptable salt thereof.

In some embodiments, there are also provided compounds of the inventionwhich are compounds of the above formula (I):

wherein

A is CH;

X is F, Cl, or Br;

Y is hydroxy, or (C₁–C₇)alkoxy; and

Z is an —NR_(a)R_(b);

where R_(a) and R_(b) are independently hydrogen, (C₁–C₇)alkyl,(C₁–C₇)alkanoyl, aryl, aryl(C₁–C₇)alkyl, or where R_(a) and R_(b)together with the nitrogen to which they are attached are a pyrrolidino,piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or1,5-benzodiazepino;or a pharmaceutically acceptable salt thereof.

In some embodiments, there are also provided compounds of the inventionwhich are compounds of the above formula (I):

wherein

A is CH;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or (C₁–C₇)alkoxy; and

Z is —NR_(a)R_(b);

where R_(a) and R_(b) are independently (C₁–C₇)alkanoyl, aryl,aryl(C₁–C₇)alkyl, or where R_(a) and R_(b) together with the nitrogen towhich they are attached are a pyrrolidino, piperidino, morpholino,1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

or a pharmaceutically acceptable salt thereof.

In some embodiments, there are also provided compounds of the inventionwhich are compounds of the above formula (I):

wherein

A is N;

X is F, Cl, or Br;

Y is hydroxy; and

Z is an —NR_(a)R_(b);

where R_(a) and R_(b) are independently hydrogen, (C₁–C₇)alkyl,(C₁–C₇)alkanoyl, aryl, aryl(C₁–C₇)alkyl, or where R_(a) and R_(b)together with the nitrogen to which they are attached are a pyrrolidino,piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or1,5-benzodiazepino;

or a pharmaceutically acceptable salt thereof.

In some embodiments, there are also provided compounds of the inventionwhich are compounds of the above formula (I):

wherein

A is N;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or (C₁–C₇)alkoxy; and

Z is —NR_(a)R_(b);

where R_(a) and R_(b) are independently (C₁–C₇)alkanoyl, aryl,aryl(C₁–C₇)alkyl, or where R_(a) and R_(b) together with the nitrogen towhich they are attached are a pyrrolidino, piperidino, morpholino,1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

or a pharmaceutically acceptable salt thereof.

The invention also provides a therapeutic method to inhibit tumor cellgrowth in a mammal, comprising administering to a mammal in need of suchtherapy, an effective amount of a compound of the invention.

The invention also provides a therapeutic method to treat cancer in amammal, comprising administering to a mammal in need of such therapy, aneffective amount of a compound of the invention.

The invention also provides a therapeutic method to treat cancer in amammal, comprising co-administering to a mammal in need of such therapy,an effective amount of a mixture of two or more compounds of theinvention, for example, a precursor compound of the formula (I).

The invention also provides the use of a compound of the invention inmedical therapy.

The invention also provides the use of a compound of the invention tomanufacture a medicament for the treatment of cancer in a mammal.

DETAILED DESCRIPTION OF THE INVENTION

Applicants have discovered that compounds of the invention of theformula (I), and in vivo metabolized products of precursor compounds ofthe invention of the formula (I), administered alone or in combination,can be useful as anti-cancer agents, and for the treatment of cancer.

The following definitions are used, unless otherwise described: halo isfluoro, chloro, bromo, or iodo. Alkyl, alkoxy, etc. denote both straightand branched groups; but reference to an individual radical such as“propyl” embraces only the straight chain radical, a branched chainisomer such as “isopropyl” being specifically referred to. When alkylcan be partially unsaturated, the alkyl chain may comprise one or more(e.g. 1, 2, 3, or 4) double or triple bonds in the chain.

“Aryl” denotes a phenyl radical or an ortho-fused bicyclic carbocyclicradical having about nine to ten ring atoms in which at least one ringis aromatic.

“Arylalkyl” or “aryl(C₁–C₇)alkyl” refer to a group of the formulaaryl(C₁–C₇)alkyl-, where aryl and (C₁–C₇)alkyl are as defined herein.

The term “amino acid,” comprises the residues of the natural amino acids(e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu,Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as wellas unnatural amino acids (e.g. taurine, phosphoserine, phosphothreonine,phosphotyrosine, hydroxyproline, gamma-carboxyglutamate, hippuric acid,octahydroindole-2-carboxylic acid, statine,1,2,3,4,-tetrahydroisoquinoline-3–carboxylic acid, penicillamine,ornithine, citruline, α-methyl-alanine, para-benzoylphenylalanine,phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). Theterm also comprises natural and unnatural amino acids bearing aconventional amino protecting group (e.g. acetyl or benzyloxycarbonyl),as well as natural and unnatural amino acids protected at the carboxyterminus (e.g. as a (C₁–C₇)alkyl, phenyl or benzyl ester or amide; or asan α-methylbenzyl amide). Other suitable amino and carboxy protectinggroups are known to those skilled in the art (See for example, T. W.Greene, Protecting Groups In Organic Synthesis; Wiley: New York, 1981,and references cited therein). An amino acid can be linked to theremainder of a compound of formula (I) through the carboxy terminus, theamino terminus, or through any other convenient point of attachment,such as, for example, through the sulfur of cysteine. A particularlypreferred amino acid is taurine (H₂N—(CH₂)₂—SO₃H), or salts thereof,which is covalently bonded at its N-terminus to the carbonyl of thecompound of formula (I).

“Heterocycle” encompasses a Z radical attached or linked to the carbonylcarbon via a nitrogen ring atom of a monocyclic, fused-bicyclic, orbridged-bicyclic, saturated or unsaturated, ring system containing fiveor twelve ring atoms consisting of carbon and one to four heteroatomseach selected from the group consisting of non-peroxide oxygen, sulfur,and at least one N(X) wherein X is absent or is H, O, (C₁–C₄)alkyl,phenyl or benzyl. Preferred heterocycles can be, for example,pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino,1,4-benzodiazepino, or 1,5-benzodiazepino.

An “isolated” compound refers to a compound that is separated from theenvironment in which it may be normally present. For example, a compoundmay be separated from nature to produce an isolated compound.

“Partially unsaturated” means, for example, a (C₁–C₇)alkyl which isoptionally partially unsaturated, means the named substituent has one ormore unsaturations, such as one or more double bonds, one or more triplebonds, or both.

A “purified” compound refers to a compound that is present in a givenquantity at a concentration of at least 50%, 60%, 70%, 80%, 90% andintermediate values thereof. For example, an isolated compound may bepresent at 51%, 52%, 53%, 54% and the like. Preferably the compound ispresent at 90% to 95% and intermediate values thereof. More preferablythe compound is present at 95% to 99%, and intermediate values thereof.Even more preferably the compound is present at 99% to 99.9% andintermediate values thereof. Most preferably the compound is present atgreater than 99.9% of a given quantity.

“Optional” or “optionally” mean that the subsequently described event orcondition may but need not occur, and that the description includesinstances where the event or condition occurs and instances in which itdoes not. For example, “optionally substituted” means that the namedsubstituent may be present but need not be present, and the descriptionincludes situations where the named substituent is included andsituations where the named substituent is not included.

The terms “include”, “for example”, “such as”, and the like are usedillustratively and are not intended to limit the present invention.

The indefinite articles “a” and “an” mean “at least one” or “one ormore” when used in this application, including the claims, unlessspecifically indicated otherwise.

It will be appreciated by those skilled in the art that compounds of theinvention having a chiral center may exist in and be isolated inoptically active and racemic forms. Some compounds may exhibitpolymorphism. It is to be understood that the present inventionencompasses any racemic, optically-active, polymorphic, orstereoisomeric form, or mixtures thereof, of a compound of theinvention, which possess the useful properties described herein, itbeing well known in the art how to prepare optically active forms (forexample, by resolution of the racemic form by recrystallizationtechniques, by synthesis from optically-active starting materials, bychiral synthesis, or by chromatographic separation using a chiralstationary phase) and how to determine, for example, anti-tumoractivity, herbicidal activity, or other therapeutic activity using thestandard tests described herein, or using other similar tests which arewell known in the art.

Specific and preferred values listed below for radicals, substituents,and ranges, are for illustration only; they do not exclude other definedvalues or other values within defined ranges for the radicals andsubstituents. The compounds of the invention include compounds offormula (I) having any combination of the values, specific values, morespecific values, and preferred values described herein.

Specifically, (C₁–C₇)alkyl can be methyl, ethyl, propyl, isopropyl,butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl, or heptyl;(C₁–C₇)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy,iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, hexyloxy, 1-methylhexyloxy,or heptyloxy; (C₁–C₇)alkanoyl can be acetyl, propanoyl, butanoyl,pentanoyl, 4-methylpentanoyl, hexanoyl, or heptanoyl; aryl can bephenyl, indenyl, or naphthyl.

When (C₁–C₇)alkyl is unsaturated or partially unsaturated, it canspecifically be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl,2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl,3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl,5-hexenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl,3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl,5-hexene-1-ynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl.

A specific value for X is F, Cl, or Br.

Another specific value for X is Cl.

Another specific value for X is Br.

A specific value for Y is hydrogen, hydroxy, or (C₁–C₇)alkoxy.

Another specific value for Y is hydrogen (—H).

Another specific value for Y is hydroxy (—OH).

Another specific value for Y is (C₁–C₇)alkoxy.

Another specific value for Y is methoxy (—OMe).

A specific value for X is Z is —NR_(a)R_(b).

Another specific value for Z is —NH₂.

Another specific value for Z is —NHCH₃.

Another specific value for Z is —N(CH₃)₂.

Another specific value for Z is pyrrolidino.

Another specific value for Z is piperidino.

Another specific value for Z is morpholino.

Another specific value for Z is 1,3-benzodiazepino.

Another specific value for Z is 1,4-benzodiazepino.

Another specific value for Z is 1,5-benzodiazepino.

Another specific value for Z is an amino acid.

Another specific value for Z is an alpha-amino acid.

Another specific value for Z is an amino acid having an alpha-carbonatom having a non-hydrogen substituent in the (L) configuration.

Another specific value for Z is an amino acid having an alpha-carbonatom having a non-hydrogen substituent in the (D) configuration.

Another specific value for Z is —NH—(CH₂)₂—SO₃H.

Another specific value for Z is —NH—CH₂—CO₂H.

Another specific value for Z is —NH—CH(CH₃)—CO₂H.

A specific group of compounds of Formula (I) are compounds wherein thecarbon bearing the methyl group is in the (D) configuration.

A preferred group of compounds of Formula (I) are compounds wherein thecarbon bearing the methyl group is in the (L) configuration.

Preferred compounds of the invention are, for example:

-   2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy}propionmethylamide;-   2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy}propiondimethylamide;-   (2-(4-(7-Chloro-2-quinoxalinyl)oxy)phenoxy)propionylamino    ethanesulfonic acid;-   (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy)propionylamino    ethanesulfonic acid;-   {2-{4-(7-Bromo-quinolin-2-yloxy)phenoxy}propionylamino}acetic acid;-   {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic    acid;-   (R)(2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy)propionylamino    ethanesulfonic acid;-   (R){2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino}acetic    acid; and-   (R){2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl    amino}acetic acid;    -   or pharmaceutically acceptable salts thereof.

Preferred compounds of the invention are, for example, of formula:

where X is Cl, Y is hydrogen or (C₁–C₇)alkoxy, and Z is —NR_(a)R_(b), oran amino acid; and compounds of the invention of the formula:

where X is Cl or Br, Y is hydrogen or (C₁–C₇)alkoxy, and Z is—NR_(a)R_(b), or an amino acid; or pharmaceutically acceptable saltsthereof.

More preferably, the compounds of the invention are of the formula:

where X is Cl or Br, Y is hydrogen or methoxy, and Z is an amino acid;or pharmaceutically acceptable salts thereof.

Still more preferably, the compounds of the invention are of theformula:

where X is Cl or Br, Y is hydrogen or methoxy, Z is an amino acid of thecorresponding (R) enantiomer(s); or pharmaceutically acceptable saltsthereof.

The invention also provides a therapeutic method to treat cancer in amammal, comprising administering to a mammal in need of such therapy, aneffective amount of a compound of the invention, for example, a compoundof the formula (I) wherein Z is taurine or glycine. Another treatmentmethod of the present invention includes co-administration of differentcompounds of the invention of the formula (I), for example, a mixture oftwo or more compounds of formula (I).

In cases where compounds are sufficiently basic or acidic to form stablenon-toxic acid or base salts, administration of the compounds as saltsmay be appropriate. Examples of pharmaceutically acceptable salts areorganic acid addition salts formed with acids which form a physiologicalacceptable anion, for example, tosylate, methanesulfonate, acetate,citrate, malonate, tartarate, succinate, benzoate, ascorbate,α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts mayalso be formed, including hydrochloride, sulfate, nitrate, bicarbonate,and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standardprocedures well known in the art, for example by reacting a sufficientlybasic compound such as an amine with a suitable acid affording aphysiologically acceptable anion. Alkali metal (e.g., sodium, potassiumor lithium) or alkaline earth metal (e.g., calcium) salts of carboxylicacids can also be made.

The compounds of Formula (I) can be formulated as pharmaceuticalcompositions and administered to a mammalian host, such as a humanpatient in a variety of forms adapted to the chosen route ofadministration, i.e., orally or parenterally, by intravenous,intramuscular, topical or subcutaneous routes.

Thus, the present compounds may be systemically administered, e.g.,orally, in combination with a pharmaceutically acceptable vehicle suchas an inert diluent or an assimilable edible carrier. They may beenclosed in hard or soft shell gelatin capsules, may be compressed intotablets, or may be incorporated directly with the food of the patient'sdiet. For oral therapeutic administration, the active compound may becombined with one or more excipients and used in the form of ingestibletablets, buccal tablets, troches, capsules, elixirs, suspensions,syrups, wafers, and the like. Such compositions and preparations shouldcontain at least 0.1% of active compound. The percentage of thecompositions and preparations may, of course, be varied and mayconveniently be between about 2 to about 60% of the weight of a givenunit dosage form. The amount of active compound in such therapeuticallyuseful compositions is such that an effective dosage level will beobtained.

The tablets, troches, pills, capsules, and the like may also contain thefollowing: binders such as gum tragacanth, acacia, corn starch orgelatin; excipients such as dicalcium phosphate; a disintegrating agentsuch as corn starch, potato starch, alginic acid and the like; alubricant such as magnesium stearate; and a sweetening agent such assucrose, fructose, lactose or aspartame or a flavoring agent such aspeppermint, oil of wintergreen, or cherry flavoring may be added. Whenthe unit dosage form is a capsule, it may contain, in addition tomaterials of the above type, a liquid carrier, such as a vegetable oilor a polyethylene glycol. Various other materials may be present ascoatings or to otherwise modify the physical form of the solid unitdosage form. For instance, tablets, pills, or capsules may be coatedwith gelatin, wax, shellac or sugar and the like. A syrup or elixir maycontain the active compound, sucrose or fructose as a sweetening agent,methyl and propylparabens as preservatives, a dye and flavoring such ascherry or orange flavor. Of course, any material used in preparing anyunit dosage form should be pharmaceutically acceptable and substantiallynon-toxic in the amounts employed. In addition, the active compound maybe incorporated into sustained-release preparations and devices.

The active compound may also be administered intravenously orintraperitoneally by infusion or injection. Solutions of the activecompound or its salts can be prepared in water, optionally mixed with anontoxic surfactant. Dispersions can also be prepared in glycerol,liquid polyethylene glycols, triacetin, and mixtures thereof and inoils. Under ordinary conditions of storage and use, these preparationscontain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion caninclude sterile aqueous solutions or dispersions or sterile powderscomprising the active ingredient which are adapted for theextemporaneous preparation of sterile injectable or infusible solutionsor dispersions, optionally encapsulated in liposomes. In all cases, theultimate dosage form should be sterile, fluid and stable under theconditions of manufacture and storage. The liquid carrier or vehicle canbe a solvent or liquid dispersion medium comprising, for example, water,ethanol, a polyol (for example, glycerol, propylene glycol, liquidpolyethylene glycols, and the like), vegetable oils, nontoxic glycerylesters, and suitable mixtures thereof. The proper fluidity can bemaintained, for example, by the formation of liposomes, by themaintenance of the required particle size in the case of dispersions orby the use of surfactants. The prevention of the action ofmicroorganisms can be brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, buffers or sodiumchloride. Prolonged absorption of the injectable compositions can bebrought about by the use in the compositions of agents delayingabsorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the activecompound in the required amount in the appropriate solvent with variousof the other ingredients enumerated above, as required, followed byfilter sterilization. In the case of sterile powders for the preparationof sterile injectable solutions, the preferred methods of preparationare vacuum drying and freeze drying techniques, which yield a powder ofthe active ingredient plus any additional desired ingredient present inthe previously sterile-filtered solutions.

For topical administration, the present compounds may be applied in pureform, i.e., when they are liquids. However, it will generally bedesirable to administer them to the skin as compositions orformulations, in combination with a dermatologically acceptable carrier,which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay,microcrystalline cellulose, silica, alumina and the like. Useful liquidcarriers include water, dimethyl sulfoxide (DMSO), alcohols or glycolsor water-alcohol/glycol blends, in which the present compounds can bedissolved or dispersed at effective levels, optionally with the aid ofnon-toxic surfactants. Adjuvants such as fragrances and additionalantimicrobial agents can be added to optimize the properties for a givenuse. The resultant liquid compositions can be applied from absorbentpads, used to impregnate bandages and other dressings, or sprayed ontothe affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts andesters, fatty alcohols, modified celluloses or modified mineralmaterials can also be employed with liquid carriers to form spreadablepastes, gels, ointments, soaps, and the like, for application directlyto the skin of the user.

Examples of useful dermatological compositions which can be used todeliver the compounds of Formula (I) to the skin are known to the art;for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S.Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157), andWortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compounds of Formula (I) can be determined bycomparing their in vitro activity, and in vivo activity in animalmodels. Methods for the extrapolation of effective dosages in mice, andother animals, to humans are known to the art; for example, see U.S.Pat. No. 4,938,949.

The amount of the compound, or an active salt or derivative thereof,required for use in treatment will vary not only with the particularsalt selected but also with the route of administration, the nature ofthe condition being treated and the age and condition of the patient andwill be ultimately at the discretion of the attendant physician orclinician.

The compound is conveniently administered in unit dosage form; forexample, containing 5 to 1,000 mg/m², conveniently 10 to 750 mg/m², mostconveniently, 50 to 500 mg/m² of active ingredient per unit dosage form.

The desired dose may conveniently be presented in a single dose or asdivided doses administered at appropriate intervals, for example, astwo, three, four or more sub-doses per day. The sub-dose itself may befurther divided, e.g., into a number of discrete loosely spacedadministrations.

The compounds of the invention are effective anti-tumor agents and havehigher potency and/or reduced toxicity as compared to XK469. Preferably,compounds of the invention are more potent and less toxic than XK469(R), and/or avoid a potential site of catabolic metabolism encounteredwith XK469, i.e., have a different metabolic profile than XK469.

The present invention provides therapeutic methods of treating cancer ina mammal, which involve administering to a mammal having cancer aneffective amount of a compound or a composition of the invention. Amammal includes a primate, human, rodent, canine, feline, bovine, ovine,equine, porcine, caprine, and the like. Cancer refers to any varioustype of malignant neoplasm, for example, colon cancer, breast cancer,melanoma and leukemia, and in general is characterized by an undesirablecellular proliferation, e.g., unregulated growth, lack ofdifferentiation, local tissue invasion, and metastasis.

The ability of a compound of the invention to treat cancer may bedetermined by using assays well known to the art. For example, thedesign of treatment protocols, toxicity evaluation, data analysis,quantification of tumor cell kill, and the biological significance ofthe use of transplantable tumors screens are documented. In addition,ability of a compound to treat cancer may be determined using the Testsas described below.

The following general methodologies were employed in evaluatingcompounds of the invention and known anti-cancer compounds:

Tumor and Animal Maintenance

Pancreatic ductal adenocarcinoma-03, mammary adenocarcinoma-16/C,mammary adenocarcinoma-17/Adr, and human melanoma LOX were used in thestudies. Tumors were maintained in the mouse strain of origin (C57B1/6for Panc-03 and C₃H for the mammary tumors). Balb/c SCID mice (B and Tcell deficient) were used for tumor maintenance and chemotherapy trialsinvolving the human melanoma LOX. Tumors were transplanted into theappropriate F₁ hybrid (B6D2F1=C57B 1/6 female× DBA/2 male) or the strainof origin for the chemotherapy trials. Individual mouse body weights foreach experiment were within 5 grams, and all mice were over 17 grams atthe start of therapy. The mice were supplied food and water ad libitum.

Chemotherapy of Solid Tumors

Animals were pooled, implanted subcutaneously with 30 to 60 mg tumorfragments by a 12 gauge trocar on day 0, and again pooled beforeunselective distribution to the various treatment and control groups.For early stage treatment, chemotherapy was started within 1 to 3 daysafter tumor implantation while the number of cells was relatively small(10⁷ to 10⁸ cells). For upstaged or advanced staged trials, the tumorswere allowed to grow for five or more days before treatment was started.Tumors were measured with a caliper twice weekly. Mice were sacrificedwhen their tumors reached 1,500 mg. Tumor weights are estimated fromtwo-dimensional measurements:

Tumor weight (in mg)=(a×b²)/2, where a and b are the tumor length andwidth in (mm), respectively.

End Points for Assessing Anti-Tumor Activity for Solid Tumors

The following quantitative endpoints were used to assess anti-tumoractivity:

a) Tumor growth delay (T−C value), where T is the median time (in days)required for the treatment group tumors to reach a predetermined size(e.g., 1,000 mg), and C is the median time (in days) for the controlgroup tumors to reach the same size. Tumor-free survivors were areexcluded from these calculations (cures are tabulated separately). Thisvalue is an important criterion of anti-tumor effectiveness because itallows the quantification of tumor cell kill.

b) Calculation of tumor cell kill for subcutaneously (SC) growingtumors. The log₁₀ cell kill was calculated from the following formula:Log₁₀ cell kill total (gross)=(T−C value in days)/(3.32)(Td)where T−C is the tumor growth delay as described above and Td is thetumor volume doubling time (in days), estimated from the best fitstraight line from a log-linear growth plot of the control group tumorsin exponential growth (100 to 800 mg range). The conversion of the T−Cvalues to log₁₀ cell kill is possible because the Td of tumorsre-growing post treatment (Rx) approximates the Td values of the tumorsin untreated control mice.

In selected cases, both for historic in vivo evaluation data as well asdata presented here, it is of value to compare log kill numbers fromtrials of markedly different testing schedules. For this purpose, anactivity table was created, and is presented below. It should be notedthat an activity rating of +++ to ++++ is needed to effect partialregression (PR) or complete regression (CR) of 100 to 300 mg size massesof most transplanted solid tumors of mice. Thus, an activity rating of +or ++ would not be scored as active by usual clinical criteria. A PR isa reduction in tumor mass to less than 50% of pretreatment size. A CR isa reduction in tumor mass to below palpable size (i.e., reduction tozero detectable mass).

Conversion of log₁₀ tumor cell kill to an activity rating Duration of Rx5 to 20 days log₁₀ kill Anti-tumor activity (gross) Highly active >2.8++++ +++ 2.0–2.8 ++ 1.3–1.9 + 0.7–1.2 − <0.7

The treatment and control groups were measured when the control grouptumors reach approximately 700 to 1,200 mg in size (median of group).The T/C value in percent is an indication of anti-tumor effectiveness: AT/C=0% means no tumor growth. A T/C=100% means no anti-tumor activity,i.e., the treated and control tumors grew equally. A T/C equal to orless than 42% is considered significant anti-tumor activity by the DrugEvaluation Branch of the Division of Cancer Treatment (NCI). A T/Cvalue<10% is considered to indicate highly significant anti-tumoractivity, and is the level used by NCI to justify a clinical trial iftoxicity, formulation, and certain other requirements are met (termedDN-2 level activity). A body weight loss nadir (mean of group) ofgreater than 20% or greater than 20% drug deaths is considered toindicate an excessively toxic dosage in most single course trials.

Drug Preparation for Injections in Mice

Compounds as their sodium salts were prepared in a 1% sodium bicarbonatesolution, H₂O or phosphate buffered saline (PBS), with pH adjusted to7.0 to 7.5 with HCl, and administered intravenously (IV) or orally (PO),at injection volumes of 0.2 mL per injection.

Amide Compound—In-Vivo Test Data

The following summarizes the results for compounds of the presentinvention prepared (Table A) and compared (Tables 1–10) with XK469.

Table 1. This data separately compared XK469 and compound 14a againstearly stage pancreatic adenocarcinoma 03 in BDF₁ male mice.

Cage 5: compound 14a was given at 120 mg/kg/inj IV, 1×/day on days 3–6,9–11 and BID on days 7–8 for a total dose of 1,320 mg/kg. There was a−0.8 g (−3.6%) body weight loss. Toxicity was not reached at this dose.Compound 14a was active, producing a 7.3% T/C and a 1.9 log cell kill(++ activity rating). This was the highest non-toxic dose (HTND).

Cage 6: Compound 14a was given at 60 mg/kg/inj IV, 1×/day on days 3–6,9–11 and BID on days 7–8 for a total dose of 660 mg/kg. There was a −0.4g (−1.8%) body weight loss and 0/5 drug deaths. This dose was minimallyactive, producing a 40% T/C and a 0.7 log cell kill (+ activity rating).

Cage 7: Compound 14a was given at 30 mg/kg IV, 1×/day on days 3–6, 9–11and BID on days 7–8 for a total dose of 330 mg/kg. There was a 0.4 g(−1.8%) body weight loss and no lethality. This dose was inactive,producing a 74% T/C and a 0.3 log cell kill {(−) inactive activityrating}.

Cage 8: Compound XK469 was given at 60 mg/kg IV on days 3–5 for a totaldose of 180 mg/kg. Treatment was stopped early due to scruffy appearanceof the mice and a −3.6 g (−15.5%) body weight loss at nadir on day 8.There were no drug deaths and mice recovered their weight on day 13.Historically, the MTD for XK469 is 450–480 mg/kg IV. Nevertheless, thissub-optimal dose of 180 mg/kg was active, producing a T/C=11% and a 1.43log cell kill (++ activity rating).

Table 2. This data separately compared XK469 and compound 14b againstearly stage pancreatic ductal adenocarcinoma 03.

Compound 14b, the mono-methylamide of XK469, was evaluated against earlystage Pancreatic Ductal Adenocarcinoma 03. Note that the compound waswater insoluble and was thus given orally.

Cage 2: XK469 Control: XK469 was injected IV, QD3–6, 10 for a total of300 mg/kg. This produced a −15% body wt loss; nadir day 8, full recoveryday 12 (estimate). This dose was highly active (1/5 cures, 3.3 log killamong those not cured, ++++ activity rating).

Cage3: 14b was given PO at 150 mg/kg/inj. BID day 3. The dose wasincreased to 250 mg/kg/inj BID days 4–7 for a total of 2,300 mg/kg. Thisproduced a −9% body wt. loss, nadir day 8 with full recovery on day 10.This dose was modestly active (T/C=39%, 0.8 log kill, + activityrating).

Cage 4 and 5: Treatments were discontinued early to conserve the scarcecompound.

Table 3. This data separately compared XK469 and compound 14c against amulti-drug resistant mammary adenocarcinoma (M17/Adr). Compound 14c (thedimethyl amide derivative of 8-methoxy XK469) was active (Cage 5).

Cage 1: No treatment control: Time to 1,000 mg=8.5 days (1.1 day Td).Tumor growth as expected.

Cage 2: (neg control) Adriamycin was given IV at 7.5 mg/kg/inj days 1, 7for a total of 15 mg/kg. This dose is historically an MTD. It wasinactive (T/C=90%).

Cage 4: XK469 was given IV at 56 mg/kg/injection QD-1–5 and 10 for atotal of 336 mg/kg. This was nicely active: T/C=9%, 4.2 log kill, ++++activity rating.

Cage 5: Compound 14c is the dimethylamide of the carboxylic acidcompound 13a. Compound 14c was given PO at 145 mg/kg/inj QD-1–3 and 7–9for a total of 870 mg/kg. Toxicity was not reached. This dose was active(T/C=20%; 1.5 log kill; ++ activity rating. Note the design of thisschedule. If adaption to the drug was going to occur, it would occur onthis schedule. One would then expect that anti-tumor activity would bemarkedly reduced (compared to 13a on a short, high dose intensityschedule). Furthermore, one would expect that the next lower dosageswould be essentially inactive on this schedule. In actual fact, theactivity was not reduced and the next lower dosages were still active.In a short, dose-intense schedule (BID-1–3), 13a (by the IV route)produced a 7% T/C and a 1.5 log kill at 162 mg/kg total dose (exactlythe log kill activity found for 14c at 870 mg/kg PO).

Cage 6: 14c was given PO at 90 mg/kg/inj QD-1–3 and 7–9 for a total of540 mg/kg. This dose was active: T/C=31%; 1.4 log kill, ++ activityrating.

Cage 7: 14c was given PO at 55.8 mg/kg/inj QD-1–3 and 7–9 for a total of334.8 mg/kg. This dose was active: T/C=31%; 1.0 log kill, + activityrating.

Cage 8: 14c was given PO at 34.6 mg/kg/inj QD-1–3 and 145 mg/kg/injQD-7–9 for a total of 538.8 mg/kg to match the total dose of cage 6.This dose was modestly active (0.9 log kill, + activity rating). Ifthere was no adaptation to the drug, the log kill should have been thesame as Cage 6. The activity was reduced (compared to Cage 6), but thefact that any activity occurred would seem to indicate that there wasnot much adaptation.

Table 4: This data separately compares XK469 and compound 14e (thedimethyl amide of 11b) against a pancreatic adenocarcinoma (P03).Compound 14e was active (Cage 2) and an improvement over XK469 (Cage 5).The higher dose requirement for compound 14e may be a disadvantage overcompound 11b (Cage 14).

This trial was designed to separately evaluate compounds 11b, 14e, andXK469 (R enantiomer).

Cage 1: No treatment control: Time to 1,000 mg=12.5 days (2.0 day Td).This was the fast growing subline of Panc-03. It is less curable thanthe older slow line. Otherwise, the behavior and growth was as expected.

Cage 2: Compound 14e was given PO at 120 mg/kg/inj 2×/day, days 3–9 fora total of 1680 mg/kg. There was no evident toxicity and the mice gainedweight. This dose (although very large) was nicely active (T/C=8.3%, 2.5log kill, +++ activity rating).

Cage 3: Compound 14e was given PO at 60 mg/kg/inj 2×/day, days 3–9 for atotal of 840 mg/kg. This dose was almost as active as the next higherdose. Considering the next lower dose (Cage 4) was almost inactiveindicated that the top dose (Cage 2) was poorly absorbed from the GI.This often happens with very large dosages of water insoluble compounds.Again, however, the dose used in Cage3 was very large (840 mg/kg total).Although active (2.2 log kill) it was not superior to compound 11b.

Cage 4: Compound 14e was given PO at 30 mg/kg/inj 2×/day, days 3–9 for atotal of 420 mg/kg. This dose was marginally active by T/C but inactiveby log kill.

Cage 5: XK469 (R) was given IV at 57 mg/kg/injection, QD 3–9 for a totalof 399 mg/kg. This is historically an adequate dose on this schedule.This produced a −6.7% body weight loss, nadir day 8, full recovery day11. This was active (T/C=4.1%, 1.7 log kill, ++ activity).

Cage 6: XK469 (R) was given IV at 38 mg/kg/injection, QD 3–9 for a totalof 266 mg/kg. This was active (T/C=8.3%, 1.4 log kill, ++ activityrating).

Cage 14: Compound 11b (racemic) was given IV at 48 mg/kg/inj QD 3–9 fora total of 336 mg/kg. This produced a −8.9% body weight loss (nadir day11). Unfortunately the mice were not weighed days 12, 13, 14, 15, 16 andby day 17 were more than a gram per mouse above the pretreatment weight.This considered, it is likely that full weight recovery occurred aroundday 15. This dose was active (T/C=0%, 2.6 log kill, +++ activityrating). This was more active than XK469 and modestly more active thancompound 14e. Note that compound 11b has a lower dose requirement thanXK469.

Table 5. This data separately compares XK469 (R) and racemic compound14f against a pancreatic adenocarcinoma (P03). Compound 14f (Cage 3) hadactivity similar to that of XK469 (R) (Cage 2). Thus, compound 14f waswell tolerated at the dose given and produced no weight loss or otheradverse symptoms. However, toxicity was not reached, and the higher doserequirement is a reflection of the racemic mix tested in this experimentbeing half-inert as the “S” form was found to be inactive (see Table 6below).

Cage 2: XK469 (R) was injected IV once daily at 45 mg/kg/inj days 3through 10 for a total dose of 360 mg/kg. A 7% body weight loss nadiroccurred d11 with full recovery by d14. This dose was active, producinga T/C of 21% and a log cell kill of 1.84 (++ activity rating).

Cage 3: Compound 14f was injected IV days 3–8 with the following doses:60 mg/kg/inj (once daily, d3–5, bid d6) 80 mg/kg (bid d7, once dailyd8). The route was then switched (for some of the mice) to SC due totail vein damage. The remainder of the treatment was as follows: 80mg/kg/inj (once daily SC d9–11, with 3 mice being injected IV on d11).The final total dose was 780 mg/kg. There was no weight loss observed.This dose was as active (T/C=10%, log cell kill=1.67, ++ activityrating).

Table 6. This data separately compares XK469 (R) and each of the “R” and“S” enantiomers of compound 14f against a human melanoma (LOX) in SCIDmice. The “S” enantiomer of compound 14f was inactive (Cage 3) and hadno toxicity associated with it other than a mild transient agitation onthe last day of injection. Compound 14f (R) (Cage 2) is the active form,with activity comparable to that of XK469 (R) (Cage 4). The “R” formproduced some toxicity: weight loss (−13.5%) and white paws (indicativeof leukopenia) which resolved within 4 days of onset. However, what ismost interesting is that both compound 14f enantiomers were bettertolerated than expected. It is also instructive to compare the totalrespective doses of XK469 and compound 14f given in Table 5 with thistrial. Note that the SCID mice tolerated a comparatively higher dose ofcompound 14f than XK469. Historically, SCID mice tolerate approximately40–50% of the conventional mouse maximum tolerated dose (MTD) of XK469.

Cage 2: Compound 14f (R) was injected IV, QD1–6, BID on day 7 for atotal dose of 700 mg/kg. There was minimal anti-tumor activity at thisdose (T/C=47%, log kill=0.8). There was a −2.8 g weight loss (−13.5%;nadir day 13) and no drug deaths. On day 14, the mice were noted ashaving white paws (indicative of leukopenia). These symptoms resolved byday 18.

Cage 3: Compound 14f (S) was injected IV, QD1–6, BID on day 7 for atotal dose of 700 mg/kg. There was minimal anti-tumor activity at thisdose (T/C=71%, log kill=0.3). The symptoms associated with the “R”enantiomer (see above) did not manifest with the “S” form of the drug.Mice treated with the “S” enantiomer gained weight during the course oftreatment (+2.0% on day 8), and exhibited mild agitation/hyperactivebehavior on the last day of treatment.

XK469 (R) was injected IV, QD1–7 for a total dose of 175 mg/kg. Therewas anti-tumor activity at this dose (T/C=34%, log kill 0.8).Historically, SCID mice tolerate approximately 50% of the conventionalmouse MTD (360 mg/kg).

Table 7. This data separately compares Compound 14g Racemic, CompoundXK469 (R), and 2-{4-{(7-bromo-2-quinolinyl)oxy}phenoxy}propionic acidcompound 11c (R) against Early Stage Mammary Adenocarcinoma 16/C. Anextended injection schedule (Q2d×7) may have yielded a better comparisonby avoiding the excessive weight loss. This evaluation was repeated onan extended injection schedule with the “R” form of compound 14g andconfirmed its enantiomeric activity and was compared with compounds 11c(R), see Table 9 below. Nonetheless, compound 14g racemic was active,producing ⅕ (20 percent) tumor free animals (day 161). The animal wasthen re-implanted with Mam16/C/71. The tumor implants grew successfully,indicating no immunologic factors were involved with the original cure.Note that compound 14g racemic was tolerated at twice the dose (moderateweight loss of −11%), indicating that either the “R” or the “S”enantiomer is inert, as was the case with 14f, the taurine derivative ofXK469.

Compound 14g Racemic: The compound was injected twice daily at 60 mg/kgIV, days 1–5 with a four hour split between injections. Injections werestopped due to tail vein damage. There was an 11% weight loss (nadir day4) with full recovery by day 10 (6 day host recovery time). This courseof treatment was active (T/C=14%, log cell kill=0.9, + activity rating).One animal remained tumor free to day 161. The animal was thenre-implanted with Mam16/C/71 to verify that it was a cure. The tumorimplants grew successfully, indicating no immunologic factors wereinvolved with the original cure.

Compound XK469 (R): The compound was injected with 50 mg/kg/inj IV days1–5 for a total dose of 250 mg/kg. Injections were stopped due to weightloss and poor physical appearance (−15.3% body weight loss day 6 withscruffy appearance). The animals developed diarrhea (noted day 7) andthe weights continued to drop (body weight loss nadir of −21.2% occurredday 7). The mice began to recover weights day 8 and had regainedpre-injection weight by day 12. Although there were no lethalities, thisdose would be considered toxic due to the excessive weight loss (>20%).The C₃H strain is not exceptionally hardy, as the usual MTD is in the360–450 mg/kg range. Nonetheless, XK469 was active (T/C=4%, log cellkill=1.6, ++ activity rating).

Compound 11c (R): This compound was given at 48 mg/kg/inj IV qd 1–5 fora total dose of 240 mg/kg. Injections were stopped due to weight lossand poor physical appearance (−17.5% body weight loss day 6 and aruffled appearance). The animals continued to drop weight and diarrheawas noted in some of the animals days 8 and 9. One animal died day 10,with the necropsy report confirming a drug death (diarrhea at death witha soft GI and a small liver and spleen). This dose would also have to beconsidered toxic due to the excessive weight loss noted at the nadir(−29.4% on day 9), though the surviving animals did recover topre-injection weight by day 13. 11c was active at this toxic dose (0%T/C, log cell kill=1.8, ++ activity rating).

Other compounds were evaluated in vivo as discussed below and assummarized in Tables 8–10.

Table 8. The “R” enantiomers of compound 11c, compound XK469, andcompound 14f were separately evaluated on an extended schedule againstearly stage murine mammary adenocarcinoma 16/C. This trial confirms theactivity of the “R” moiety of 14f. Note the similarities in activity for11c (R) (Cage 2), XK469(R) (Cage 3), and 14f (R) (Cage 4), except forthe higher dose requirement of 14f. The “R” enantiomers were essentiallyequivalent in activity, producing>4.0 log cell kill (++++ activityrating) on the extended, intermittent injection schedule. All threeagents were well tolerated with moderate body weight loss noted forXK469 (−7.4%). 14f and 11c (R) produced more modest weight loss (−3.0%and −4.3% respectively). In keeping with the rapid host recovery timesof this series, all weight loss was fully recovered within 2–4 days ofnadir.11c (R): Cage 2 was injected with 60 mg/kg/inj every other day, startingon day 1 for a total dose of 480 mg/kg. On this extended schedule, 11c(R) was well tolerated and no adverse effects were noted. There wasmodest weight loss of −1.14 g (−4.3%); the nadir occurred on d14, withfull recovery by d17. This dose was highly active (0% T/C, 4.8 log cellkill, activity rating:++++) but there were no cures.XK469 (R): Cage 3 was injected with 60 mg/kg/inj on a Q2d×8 schedulestarting on day 1 for a total dose of 480 mg/kg. On this extendedschedule XK469 (R) was also well tolerated, producing a body weight lossof −2.0 g (7.4%); the nadir occurred d17, with full weight recovery byd20. XK469 (R) was highly active on this schedule (T/C=0%, log cellkill=5.4, ++++ activity rating). There were no cures.14f (R): Cage 4 was injected with the following escalation of doses: 80mg/kg/inj (d1), 100 mg/kg (d3), 120 mg/kg (d4), 160 mg/kg (d5), 200mg/kg (d7, 9) and 250 mg/kg (d11, 13, 15) for a total dose of 1610mg/kg. 14f (R) was well tolerated on this dose/schedule producing amodest weight loss of −0.8 g (−3.0%). Weight loss nadir occurred on d14,with full recovery by day 16. The “R” enantiomer of 14f was highlyactive (T/C=0%, log cell kill=4.2, ++++ activity). There were no adversesymptoms noted post injection of compound 14f (R) and no cures.

Cage 5 was injected with the following escalation of doses: 50 mg/kg/inj(d1), 65 mg/kg (d3), 75 mg/kg (d4), 100 mg/kg (d5) and 125 mg/kg (d6, 7,9,) for a total dose of 665 mg/kg. Injections were stopped at this pointto conserve drug supplies. This lower dose of 14f (R) was also active(14% T/C, 1.8 log cell kill, ++ activity rating).

Table 9. This evaluation confirmed the activity of the “R” enantiomer ofcompound 14g. The lower limit of solubility for 14g (R) precluded anevaluation of this compound by the IV route, so IP injections were giveninstead. With the exception of a higher dose requirement for 14g (R),the compound was equivalent in efficacy (Cage 3, ++ activity rating) tothat of the parent, 11c (R) (Cage 5, ++ activity rating) by this routeand short intense schedule of administration.

The “R” enantiomers of 14g and 11c were given IP on a daily scheduleagainst early stage Pancreatic Adenocarcinoma 03. The IP route was usedfor two reasons. First, the “R” form of 14g has a solubility limit of 25mg/kg (0.2 ml/inj). This is approximately 40% of the dose given IV withthe racemic mix (60 mg/kg, see Table 7). The “R” form's low solubilitymade IV injection a technically unsuitable route of administration dueto an excessive number of injections required to deliver an adequatetotal dose. Second, although this drug series is just as active orally,the PO route was not used for this trial because of the possibility thatthe amide bond would be subject to cleavage by the strong acids presentin the stomach. For this same reason, 14g (R) was prepared without acidor base to minimize any possibility of cleavage regenerating the parentcompound (11c (R)).

14g (R): Cage 2 was injected IP with 75 mg/kg/inj BID (2×/day) on days3–5 for a total dose of 450 mg/kg. The animals were noted as havingincreased urinary output and a sunken appearance, indicating possiblediuretic effect from the drug. The dose was toxic, with one drug deathoccurring day 10. Necropsy results indicated a normal size stomach andliquid filled upper and lower GI (diarrhea). A mean body weight loss of23.4% occurred day 9, with the remaining surviving animals recovering topre-injection weight by day 17. Although this dose was toxic, 14g (R)was active (T/C=0%, log cell kill=1.52, ++ activity rating). Inhindsight, an extended every other day injection schedule would bebetter tolerated.

Cage 3 was injected IP with 45 mg/kg/inj BID on days 3–7 for a totaldose of 450 mg/kg. Injections were stopped as these animals were alsoexhibiting signs of diuretic effect. The mean body weight loss of 6.7%occurred d9, with full weight recovery by d12. This dose was active onthis schedule, producing a T/C=12.6%, log cell kill=1.72, ++ activityrating.

11c (R): Cage 4 was injected IP with the following doses: 50 mg/kg/injdays 3–5, 7 and 60 mg/kg/inj. day 6 for a total dose of 260 mg/kg.Injections were stopped due to onset of weight loss (nadir of −16.7%with full recovery by day 17) and poor appearance (scruffy, hunched,high urinary output). One drug death occurred on d 11. Necropsy resultsindicated normal spleen, liquid filled GI (upper and lower) and palepaws. In hindsight, an extended every other day schedule would have beenbetter tolerated.

Cage 5 was injected with 30 mg/kg/inj (days 3–5,7) and 37.5 mg/kg/inj(day 6) for a total dose of 157.5 mg/kg. This dose produced no weightloss or external signs of distress. The dose was active (T/C=26%, logcell kill=1.58, ++ activity rating).

Table 10. The R enantiomers of 14h (R), 14i (R), 11c (R) and XK469 (R)were evaluated on extended injection schedules against early stagepancreatic adenocarcinoma 03. Low water solubility limits encounteredwith 14h (R) (this trial) and 14g (R) previously (see Table 9),precluded IV administration for technical reasons (too many injections).The oral (PO) route, which is the preferred alternate route for thisdrug series, was deemed not feasible due to potential cleavage of theamide bonds of 14h and 14i (R) by the low pH environment present in thestomach. Thus, for this test, all compounds initially were to be givenIP, in an attempt to identify a suitable alternate route ofadministration. However, sustained pain production was noted after thefirst IP injection of 14i (R). As this compound retained good watersolubility, the route was switched to IV for subsequent injections (Cage4). At a total dose of 455 mg/kg, given on an extended schedule, 14i (R)produced a 10% T/C, 1.6 log kill (++ activity rating) confirmingactivity of the R form of the compound. Considering the modest weightloss, it is likely that higher dosages could have been administered(with likely greater efficacy). However, 14i (R) does require a highertotal dose than the parent compound, XK469 (R). In Cage 7, XK469 (R) at350 mg/kg total dose, given IP on the same schedule produced a 5% T/C, a2.2 log kill, for a +++ activity rating.14h (R): given IP also produced pain. Unlike 14i (R), this compound hadmuch lower water solubility. So to achieve an adequate total dose, theroute was switched to SC for subsequent injections (SC behind neck, thetumors were SC bilateral, on the sides of the mouse midway between thelegs). On an extended injection schedule, at a total dose of 615 mg/kg,14h (R) produced a 3% T/C, 1.9 log kill (++ activity rating), confirmingthe activity of the R form of the compound. However, 14h (R) was lessactive and required a higher total dose than the parent compound, 11c(R) (400 mg/kg total dose), given IP on a similar extended schedule inCage 11 (0% T/C, 3.3 log kill, 1/5 tumor free on day 148. This animalwas then re-implanted with PO3/142. The tumor implants grewsuccessfully, indicating no immunologic factors were involved with theoriginal cure.14i (R): Cage 2: A dose of 135 mg/kg was injected IP on day 3 only. Nofurther injections were given due to the prolonged pain responseproduced by this route and dose post injection. The mice displayedhind-leg stretching and flattening for up to 1 hour post injection—aclassic response to pain. There was a pronounced body weight loss of−1.6 g (−6.7%) on day 7 (nadir) with full recovery by day 9. Despite thelow total dose delivered, 14i (R) was active by the IP route, producinga 10% T/C and a 1.1 log cell kill (+ activity rating).

Cage 3: A dose of 80 mg/kg was injected IP on day 3 only. As for Cage 2above, further injections were discontinued due to the prolonged painresponse produced (one hour duration). There was one injection death onday 4 (upper GI inflammation was noted at necropsy). Despite the lowdose delivered, 14i (R) was active in this group as well although justbarely (37% T/C, 0.7 log kill, + activity rating).

Cage 4: An initial dose of 50 mg/kg IP, given on day 3 did not cause anyadverse reaction post injection. The route was switched to IV due to thesignificant pain produced by the higher doses, and injections continuedon an every other day schedule (Q2d×7) through day 15 for a total doseof 455 mg/kg. A modest weight loss nadir of −0.8 g (−3.4%) occurred onday 7 with full recovery by day 11 (weight gain during treatment). Thisdose was moderately active (8% T/C, 1.6 log kill, ++ activity rating).Considering the modest weight loss, it is likely that substantiallyhigher dosages could have been administered (which would have producedgreater efficacy).

XK469 (R): Cage 5: SC injections of 80 mg/kg/inj were given qd 3–5 for atotal dose of 240 mg/kg. Injections were stopped due to a significant−16.7% body weight loss (nadir occurred d9 with full recovery by d14).There was one drug death on day 10 (necropsy: diarrhea, liquid filledinflamed GI indicative of GI epithelial damage). This route/schedule wasrun to determine if XK469 (and the series) was active by the SC route.In hindsight, a lower dose given on an intermittent schedule may havebeen better tolerated. Nonetheless, XK469 (although at a LD20 dose onthis schedule) was active by the SC route, producing a 9% T/C and a 1.6log kill, ++ activity rating.

Cage 6: IP injections of 80 mg/kg/inj were given on days 3 and 5.Sporadic hind-leg stretching (transient pain) lasting 1–2 minutes postinjection was noted. On days 7 and 9, the mice were not injected as theyhad a scruffy appearance, and sustained a body weight loss of −11.6%(nadir on day 9). Full weight recovery occurred on day 11 and injectionswere resumed on days 11 and 13 for a total of 320 mg/kg. XK469 was veryactive by the IP route on this schedule (5% T/C, 2.0 log cell kill, +++activity rating).

Cage 7: IP injections of 50 mg/kg/inj were given on a Q2d×7 schedulestarting on day 3 for a total dose of 350 mg/kg. This dose was welltolerated, with no adverse symptoms noted post injection. A body weightloss nadir of −0.8 g (−3.0%) occurred on day 8 with full recovery on day11 (wt. gain during treatment). XK469 (R) was very active by the IProute on this extended intermittent schedule, producing a 5% T/C and a2.2 log kill (+++ activity rating).

14h (R): Cage 8: An initial dose of 135 mg/kg was injected IP on day 3.There was transient puffiness and a pain reaction noted post injectionso subsequent injections were given by the SC route. 14h (R) wasinjected SC on days 5 and 7 (135 mg/kg) with no reaction noted postinjection. On day 9, the animals were rested due to a slightly scruffyappearance and a body weight loss (nadir d9) of −2.8 g (−11.6%).Although the mice did not fully recover their starting weight until day20, they steadily gained weight and improved in appearance from day 10on and so treatment resumed on day 11 (50 mg/kg), and continued on days13 and 15 (80 mg/kg) for a total dose of 615 mg/kg. 14h (R) was activeat this dose, producing a 3% T/C and a 1.9 log cell kill (++ activityrating).

Cage 9: IP injections of 80 mg/kg/inj were given on days 3, 5 and 7.Sporadic hind-leg stretching (transient pain) lasting 1–2 minutes postinjection was noted. On day 9, the mice were rested due to a scruffyappearance and weight loss (nadir of −13.3% occurred on day 10).Although the mice did not fully recover their starting weight until day20, they steadily gained weight and improved in appearance from day 11on and so injections resumed on days 11, 13 and 15 for a total of 480mg/kg. 14h (R) was also very active at this dose, producing a 6% T/C,and a 1.7 log cell kill, ++ activity rating).

Cage 10: IP injections of 50 mg/kg/inj were given on a Q2d×7 schedulestarting on day 3 for a total dose of 350 mg/kg. This dose was welltolerated, with no adverse symptoms noted post injection. A moderatebody weight loss nadir of −1.6 g (−6.6%) occurred on day 8 with fullrecovery on day 15 (wt. gain during treatment). 14h (R) was modestlyactive by the IP route on this extended intermittent schedule, producinga 16.5% T/C and a 1.0 log kill (+ activity rating).

11c (R): Cage 11: IP injections of 80 mg/kg/inj were given on days 3 and5. Sporadic hind-leg stretching (transient pain) lasting 1–2 minutespost injection was noted. On days 7 and 9, the mice were rested due to ascruffy appearance and a pronounced body weight loss of −18% (nadiroccurred on day 9). Although the mice did not fully recover theirstarting weight until day 16, they steadily gained weight and improvedin appearance from day 11 on and so injections resumed on days 11, 13and 15 for a total of 400 mg/kg. Although the weight loss sustained bythese mice in this treatment group indicate a near LD10 dose (20% bodyweight loss is considered excessively toxic by NCI standards), 11c (R)was highly active by the IP route, producing a 0% T/C, and a 3.3 logcell kill, ++++ activity rating). One mouse remained tumor free to day148, at which time the animal was re-implanted with PO3/142. The tumorimplants grew successfully, indicating no immunologic factors wereinvolved with the original cure.

Cage 12: IP injections of 50 mg/kg/inj were given on a Q2d×7 schedulestarting on day 3 for a total dose of 350 mg/kg. This dose was welltolerated, with no adverse symptoms noted post injection. A moderatebody weight loss of −0.8 g (−3.2%) occurred on day 8 (nadir) with fullrecovery on day 11 (wt. gain during treatment). 11c (R) was active bythe IP route on this extended intermittent schedule, producing a 3% T/Cand a 1.4 log kill (++ activity rating).

General Preparative Procedures

Preparation of {4-{(7-Substituted-2-quinolinyl)oxy}phenoxy} propionicacid compounds (Schemes I–II) As shown in Scheme I, a one-potpreparation of trans-3-ethoxyacryloyl chloride (3) by reaction of ethylvinyl ether (1) and oxalyl chloride (2), with subsequentdecarboxylation, has been described by Tietze et al., Synthesis,1079–1080 (1993).

The amidation of the meta-substituted anilines (4a–e) with 3, i.e., theconversion to 5a–e, was modeled after the procedure described byCampbell and Roberts (U.S. Pat. No. 4,710,507) for preparation oftrans-N-(4-bromo-3-methylphenyl)-3-ethoxypropenamide. Cyclization of thelatter to a mixture of 5-(7a–e) and 7-substituted quinolin-2-ols (6a–e)was effected in either concentrated sulfuric or hydrochloric acid(Campbell and Roberts). The mixture, in turn, was transformed to thecorresponding 2-chloroquinoline derivatives (8a–e) and (9a–e), onrefluxing with phosphorous oxychloride (Campbell and Roberts). Themajority of the 7-substituted derivatives (8a–e) separated from theregioisomer (9a–e) on fractional crystallization. The residue yieldedadditional 8a–c, following column chromatography over silica gel. Asillustrated in Scheme II, the 2-chloroquinolines 8a–e were coupled with2-(4-hydroxyphenoxy)propionic acid (20) using either NaH or K₂CO₃ inrefluxing DMF followed by acidification to give the acids (21a–e)according to the following procedure. To a solution of the7-substituted-2-chloroquinoline and 2-(4-hydroxyphenoxy)propionic acid(1 eq) dissolved in DMF (5 mL/mmol), 60% NaH (3 eq) was added inportions and the mixture heated at gentle reflux for 2 hours. Aftercooling it was concentrated to give a solid to which water was added andthe solution was filtered through Celite, then washed with water. Thefiltrate was extracted with ether and the aqueous layer was acidifiedwith 1M HCl to pH 3–4.

2-(4-Hydroxyphenoxy)propionic acid (1 eq) dissolved in DMF (5 mL/mmol),60% NaH (3 eq) was added in portions and the mixture heated at gentlereflux for 2 hours. After cooling it was concentrated to give a solid towhich water was added and the solution was filtered through Celite, thenwashed with water. The filtrate was extracted with ether and the aqueouslayer was acidified with 1M HCl to pH 3–4. After cooling, the solid wascollected, dried, dissolved in AcOEt and filtered through silica gel.The filtrate was concentrated to a small volume, the solid was collectedand recrystallized from AcOEt-heptane to afford the propionic acidcompounds (11a–e). The reaction can alternatively be carried out usingK₂CO₃ (2.5 eq) instead of NaH but the reaction times are typicallylonger, for example, about 12 hours. These acids can also be convertedto their metal salts (12a–e) by reacting with metal hydroxides.

XK469, which possesses a single stereogenic center at C-2 of thepropionic acid moiety, is generally prepared in the form of a racemicmixture. The R-(+) forms of 11b and 11c were prepared by etherificationof commercially available R-(+)-2-(4-hydroxyphenoxy)propionic acid with8b and 8c. Chiral HPLC of the R-form of 11b and 11c, indicated that theyhad both been obtained in >99% ee. HPLC separations of both racemic 11band 11c were carried out using ASTEC Chirobiotic T 250×4.6 mm, 65% H₂O,35% CH₃OH, 20 mM NH₄NO₃ at 1 mL/min with detection at 250 nm. The samecolumn, solvent system and spectral measurements were employed todetermined the enantiomeric purity of (R−)-11b and (R−)-11c.

The invention will now be illustrated by the following non-limitingexamples:

Preparation of {4-{(7-Substituted-2-quinolinyl)oxy}phenoxy} propionicamide compounds (A=CH) and{4-{(7-Substituted-2-quinoxalinyl)oxy}-phenoxy}propionic amide compounds(A=N) (Scheme III) A description of the conversion of representative2-{4-((7-bromo and 7-chloro-2-quinolinyl)oxy)phenoxy}propionic acidcompounds to their corresponding mono- and di-substituted propionamidederivatives follows. Compounds of formula 14 were prepared from thecorresponding compounds of formula 13a–d using the reaction conditionsillustrated below. The designation of specific substituents X, Y, A, Z,R_(a) and R_(b) in product compounds of formula 14a–i are listed inTable A.

The reaction of 2-{4-{(7-bromo-2-quinolinyl)oxy}phenoxy}propionic acid11-c (A=CH) (Scheme II) with thionyl chloride generated the intermediateacid chloride, which on treatment with methylamine in THF, gave themonomethyl amide 14d (Table A) in good yield. Similarly, the reaction ofthe acid chloride of compound 11b (X═Cl, Y═H, A=CH) in THF withdimethylamine afforded the N,N′-dimethylamide 14e (Table A).

Treatment of the acid chlorides of (RS)-, or (R+)- or (S−)-, of compoundXK469 (A=N) and compound 11c (A=CH), respectively, with the amino acidtaurine (NH₂CH₂CH₂SO₃H) in THF and in the presence of 1M NaOH providedthe corresponding {(RS)-, (R+)- or (S−)-} taurine compounds in goodyield in the form of sodium salt (14f and 14g) in good yield. The samereactions with the amino acid glycine (NH₂CH₂CO₂H) can afford theN-amino acid derivative (14h and 14i of Table A).

Scheme III

Compound X Y R 11b Cl H H 11c Br H H 13a Cl OCH₃ H 13b Cl H CH₃ StartingCompound Reaction Conditions Product 13b MeOH/NH₃ 14a XK469 SOCl₂,NH₂CH₃/THF 14b 13b SOCl₂, NH(CH₃)₂/THF 14c 11c SOCl₂, NH₂CH₃/THF 14d 11bSOCl₂, NH(CH₃)₂/THF 14e XK469 SOCl₂, NaOH/THF, NH₂(CH₂)₂SO₃H, H⁺ 14f 13aSOCl₂, NaOH/THF, NH₂(CH₂)₂SO₃H, H⁺ 14g 13a SOCl₂, NaOH/THF,NHCH₂C(═O)OM, H⁺ 14h XK469 SOCl₂, NaOH/THF, NHCH₂C(═O)OM, H⁺ 14i

TABLE A Compounds prepared according to Scheme III. Compound X Y A Z 14aCl H N NH₂ 14b Cl H N NHCH₃ 14c Cl OCH₃ N N(CH₃)₂ 14d Br H CH NHCH₃ 14eCl H CH N(CH₃)₂ 14f Cl H N NH(CH₂)₂SO₃M taurine salt 14g Br H CHNH(CH₂)₂SO₃M taurine salt 14h Br H CH NHCH₂CO₂M glycine salt 14i Cl H NNHCH₂CO₂M glycine salt

EXAMPLE 1

2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy} propionmethylamide (14d) Amixture of 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid 11c(0.20 g, 0.52 mmol) and SOCl₂ (0.40 mL, 0.66 g, 5.4 mmol) was heated for1 h, then concentrated to give a yellowish solid. The latter wasdissolved in THF (10 mL); methylamine (2 M in THF) was added until themixture was basic and then concentrated to give a yellowish solid. Water(10 mL) and saturated NaHCO₃ were added until pH 8, and the mixtureextracted with AcOEt (2×25 mL). The combined extracts were washed withsaturated NaCl (10 mL) and after drying (MgSO₄), filtered through silicagel and concentrated to give an off white solid. The latter wasrecrystallized from EtOH-heptane to give the title compound 14d (0.20 g,95%) as white crystals; mp 150–151° C.; ¹H NMR (400 MHz, CDCl₃) δ 8.06(d, J=8.8 Hz, 1H), 7.93 (d, J=1.6 Hz, 1H), 7.59 (d, J=9.2 Hz, 1H), 7.48(dd, J=8.4, 1.6 Hz, 1H), 7.19–7.14 (m, 2H), 7.07 (d, J=8.8 Hz, 1H),6.97–6.91 (m, 2H), 6.56 (bs, 1H), 4.68 (q, J=6.4 Hz, 1H), 2.87 (d, J=5.2Hz, 3H), 1.60 (d, J=6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.0,162.6, 154.2, 148.0, 147.3, 139.8, 130.4, 128.8, 128.4, 124.4, 124.2,123.1, 116.5, 113.3, 75.9, 26.2, 19.1. MS (EI) m/z (%) 400 (M⁺, 33), 342(40), 328 (6), 316 (22), 298 (7), 206 (17), 189 (5), 149 (6), 137 (18),127 (17), 121 (10), 109 (9), 95 (16), 86 (20), 81 (51), 69 (100), 57(19), 55 (21), 45 (7). HRMS (EI) m/z 400.0426 (Calcd for C₁₉H₁₇N₂BrO₃400.0423).

EXAMPLE 2

2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy}propiondimethylamide (14e) Amixture of 2-{4-[(7-chloro-2-quinolinyl)oxy]phenoxy}propionic acid 13c(0.45 g, 1.3 mmol) and SOCl₂ (0.48 mL, 0.78 g, 6.6 mmol) was refluxedfor 1 h. After cooling the solution was concentrated under reducedpressure to give a yellow liquid, which was dissolved in THF (15 mL).Dimethylamine (2 M in THF) was added until the mixture was basic andthen concentrated to give a light brown solid. Water (15 mL) andsaturated NaHCO₃ were added to pH 8 and the mixture extracted with AcOEt(2×25 mL). The combined extracts were washed with saturated NaCl (2×10mL), and after drying (MgSO₄), were concentrated to give a yellowliquid. The latter was purified by flash column chromatography (1:4hexanes:AcOEt) (R_(f)=0.44 (1:4 hexanes:AcOEt)) to give a white solid,which crystallized from EtOH-heptane to give the title compound 14e,(0.42 g, 87%) as an off white solid, mp 148–150° C.; ¹H NMR (400 MHz,CDCl₃) δ 8.05 (d, J=9.2 Hz, 1H), 7.75 (d, J=2.4 Hz, 1H), 7.65 (d, J=9.2Hz, 1H), 7.34 (dd, J=8.8, 2.4 Hz, 1H), 7.17–7.11 (m, 2H), 7.03 (d, J=8.0Hz, 1H), 6.96–6.90 (m, 2H), 4.96 (q, J=6.4 Hz, 1H), 3.14 (s, 3H), 2.97(s, 3H), 1.62 (d, J=7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.3,162.8, 154.6, 147.6, 147.2, 139.6, 135.9, 128.7, 127.2, 125.8, 124.1,122.9, 115.9, 113.0, 74.5, 36.8, 36.6, 17.9. IR (KBr) 1650, 1605, 1590,1570, 1485, 1435, 1420, 1410, 1395, 1370, 1365, 1340, 1295, 1280, 1250,1225, 1190, 1160, 1140, 1115, 1100, 1080, 1065, 1030, 1005, 990, 960,940, 875, 850, 825, 805, 790, 770, 730, 625, 605, 505, 480, 450, 360cm⁻¹. MS (EI) m/z (%) 370 (M^(+b , 30)), 298 (48), 270 (21), 254 (15),236 (3), 220 (3), 191 (8), 135 (3), 127 (11), 105 (3), 100 (100), 91(4), 72 (47), 69 (6), 57 (6), 55 (8), 44 (6), 28 (15). Anal. Calcd forC₂₀H₁₉N₂ClO₃: C, 64.78; H, 5.16; N, 7.55. Found: C, 64.55; H, 5.15; N,7.47.

EXAMPLE 3

Sodium (2-(4-(7-chloro-2-quinoxalinyl)oxy)phenoxy)propionylaminoethanesulfonate (14f) A mixture of (XK469)(0.49 g, 1.4 mmol) and SOCl₂(0.52 mL, 0.85 g, 7.1 mmol) was heated for 1 h before concentrating togive a yellow liquid, which was dissolved in THF (1.5 mL). The resultingsolution and 1 M NaOH (1.6 mL, 1.6 mmol) were added dropwise at equalrates to a solution of sodium β-aminoethylsulfonate (taurine) (0.17 g,1.3 mmol) in 1 M NaOH (1.4 mL, 1.4 mmol) at 0° C. After stirring for ½ hat rt the mixture was diluted with water (10 mL) and 1 M H₂SO₄ addeduntil pH 3. The mixture was washed with ether (2×25 mL) and 1 M NaOHadded to the aqueous layer until pH 7, before it was concentrated anddried to give a yellowish solid. The latter was triturated with hotCH₃OH and the insoluble material filtered off before the filtrate wasconcentrated and recrystallized from CH₃OH-EtOH to give the titlecompound 14f; (0.47 g, 74%) as white crystals, mp 250–252° C.; ¹H NMR(400 MHz, CD₃OD) δ 8.68 (s, 1H), 7.99 (d, J=8.8 Hz, 1H), 7.71 (d, J=1.6Hz, 1H), 7.61 (d, J=8.8 Hz, 1H), 7.21 (d, J=9.2 Hz, 2H), 7.06 (d, J=8.8Hz, 2H), 4.72 (q, J=6.4 Hz, 1H), 3.74–3.58 (m, 2H), 3.03–2.88 (m, 2H),1.57 (d, J=6.8 Hz, 3H). IR (KBr) 3260, 1650, 1565, 1550, 1500, 1485,1440, 1395, 1370, 1330, 1290, 1260, 1230, 1195, 1140, 1105, 1090, 1055,1000, 915, 835, 820, 805, 770, 695, 665, 635, 610, 530, 500, 430 cm⁻¹.MS (EI negative ion) m/z (%) 450 (M^(−Na), 100), 343 (3).

Chiral HPLC separation (S enantiomer 19.6 minutes, R enantiomer 23.2minutes) using Regis (R,R)-Whelk-O1 250×4.6 mm, 75% Hexanes, 25% 2—PrOH,15 mM AcONH₄ at 1.5 mL/min with detection at 245 nm.

The same series of reactions was performed with compound XK469 (R+) or(S−), to produce the corresponding enantiomer of compound 14f; (R+) mp250–252° C., [α]_(D)=+20.2° (c=0.50, H₂O); or (S−) 251–253° C.,[α]_(D)=−20.0°(c=0.50, H₂O).

EXAMPLE 4

A. Racemic. Sodium(2-(4-(7-bromo-2-quinolinyl)oxy)phenoxy)propionylamino ethanesulfonate(14g) A mixture of compound 11c (X=7—Br; A=CH)(prepared according to J.Med. Chem., 2002, 45, 3130, at 3135, see compound 11d) (0.23 g, 0.59mmol) and SOCl₂ (0.45 mL, 0.73 g, 6.2 mmol) was heated for 1 h beforeconcentrating to give a yellow solid which was dissolved in THF (2.0mL). This solution and 1 M NaOH (0.7 mL, 0.7 mmol) were added dropwiseto a solution of taurine (0.07 g, 0.55 mmol) in 1 M NaOH (0.6 mL, 0.6mmol) at 0° C. After stirring for ½ h at rt the mixture was diluted withwater (5 mL) and 1 M H₂SO₄ added until pH 3. The mixture was washed withether (2×10 mL) and 1 M NaOH added to the aqueous layer until pH 7before it was concentrated and dried to give the title compound 14g asan off-white solid. This was mixed with hot CH₃OH and the insolublematerial filtered off before the filtrate was concentrated andrecrystallized from CH₃OH to give (0.21 g, 75%) as off white crystals.mp 231–233° C.; ¹H NMR (400 MHz, CD₃OD) δ 8.26 (d, J=9.2 Hz, 1H), 7.87(d, J=1.6 Hz, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.55 (dd, J=8.8, 1.6 Hz, 1H),7.18–7.10 (m, 3H), 7.08–7.02 (m, 2H), 4.72 (q, J=6.4 Hz, 1H), 3.71–3.60(m, 2H), 3.04–2.90 (m, 2H), 1.57 (d, J=7.6 Hz, 3H).B. (R) enantiomer. Sodium (2-(4-(7-bromo-2-quinolinyl)oxy)phenoxy)propionylamino ethanesulfonate {14g (R)} The above procedure (A.Racemic) was repeated with the exception that compound 11c was obtainedfrom etherification of 8c and commercially availableR-(+)-2-(4-hydroxyphenoxy)propionic acid 10.

(R) enantiomer: mp 251–253° C., [α]_(D)=+20.0° (c=0.25, CH₃OH). ChiralHPLC separation (S enantiomer 21.8 minutes, R enantiomer 25.7 minutes)using Regis (R,R)-Whelk-O1 250×4.6 mm, 75% Hexanes, 25% 2-PrOH, 15 mMAcONH₄ at 1.5 mL/min with detection at 230 nm.

EXAMPLE 5

A. Racemic.{2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino}acetic acid(14h). The procedure of Example 4 was repeated with the exception that asolution of glycine was substituted for a solution of taurine to providethe compound of the formula corresponding to 14h where R is H, that is,Z is —NHCH₂CO₂H, mp 157–159° C., or salts thereof).B. (R) enantiomer.{2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino}acetic acid(14h (R)). The above procedure (A. Racemic) was repeated with theexception that compound 11c was obtained from etherification of 8c andcommercially available R-(+)-2-(4-hydroxyphenoxy)propionic acid 10.

(R) enantiomer: mp 172–174° C., [α]_(D)=+8.6° (c=0.50, CH₃OH). ChiralHPLC separation (S enantiomer 24.0 minutes, R enantiomer 29.0 minutes)using Regis (R,R)-Whelk-O1 250×4.6 mm, 65% Hexanes, 35% 2-PrOH, 15 mMAcONH₄ at 1 mL/min with detection at 220 nm.

EXAMPLE 6

A. Racemic {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionylamino}acetic acid (14i). The procedure of Example 3 wasrepeated with the exception that a solution of glycine was substitutedfor a solution of taurine to provide the compound of the formulacorresponding to 14i where R is H, that is, Z is —NHCH₂CO₂H, mp 188–190°C., or salts thereof).B. (R) enantiomer. {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionylamino}acetic acid (14i (R)). The above procedure (A. Racemic) wasrepeated with the exception that XK469 was obtained from etherificationwith commercially available R-(+)-2-(4-hydroxyphenoxy)propionic acid 10.

(R) enantiomer: mp 190–192° C., [α]_(D)=+19.0° (c=0.50, 0.1 M NaOH).Chiral HPLC separation (S enantiomer 21.7 minutes, R enantiomer 26.7minutes) using Regis (R,R)-Whelk-O1 250×4.6 mm, 65% Hexanes, 35% 2-PrOH,15 mM AcONH₄ at 1 mL/min with detection at 240 nm.

EXAMPLE 7

The following illustrates representative pharmaceutical dosage forms,containing a compound of formula I (‘Compound X’), for therapeutic orprophylactic use in humans.

(i) Tablet 1 mg/tablet ‘Compound X’ 100.0 Lactose 77.5 Povidone 15.0Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 Magnesiumstearate 3.0 300.0 (ii) Tablet 2 mg/tablet ‘Compound X’ 20.0Microcrystalline cellulose 410.0 Starch 50.0 Sodium starch glycolate15.0 Magnesium stearate 5.0 500.0 (iii) Capsule mg/capsule ‘Compound X’10.0 Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch120.0 Magnesium stearate 3.0 600.0 (iv) Injection 1 (1 mg/mL) mg/mL‘Compound X’ (free acid form) 1.0 Dibasic sodium phosphate 12.0Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodiumhydroxide solution q.s. (pH adjustment to 7.0–7.5) Water for injectionq.s. ad 1 mL (v) Injection 2 (10 mg/mL) mg/ml ‘Compound X’ (free acidform) 10.0 Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1Polyethylene glycol 400 200.0 01 N Sodium hydroxide solution q.s. (pHadjustment to 7.0–7.5) Water for injection q.s. ad 1 mL (vi) Aerosolmg/can ‘Compound X’ 20.0 Oleic acid 10.0 Trichloromonofluoromethane5,000.0 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane5,000.0

The above formulations may be obtained by conventional procedures wellknown in the pharmaceutical art.

All publications, patents, and patent documents are incorporated byreference herein, as though individually incorporated by reference. Theinvention has been described with reference to various specific andpreferred embodiments and techniques. However, it should be understoodthat many variations and modifications may be made while remainingwithin the spirit and scope of the invention.

TABLE 1 Evaluation of Compound 14a and XK469 Against Early StagePancreatic Adenocarcinoma 03 in BDF₁ Male Mice Mean Drug Treatment/Total Body Wt. Percent Deaths Median tumor Drug Dosage Loss in Body Wt.Day of Wt. (days of burden in mg Cage Route Schedule mg/kg g/mouse LossLoss Nadir death) on day 14 (range) 1 No Rx — — −0.4 −1.8 5 0/5 1724(580–2932) 5 14a (PO) QD3–6, 1,320 −0.8 −3.6 8 0/5 126 (63–385) 9–11 BID7–8 6 14a (PO) QD3–6, 660 −0.4 −1.8 5 0/5 695 (342–1389) 9–11 BID 7–8 714a (PO) QD3–6, 330 −0.4 −.8 6 0/5 1273 (343–1975) 9–11 BID 7–8 8 XK469(IV) QD 3–5 180 −3.6 −15.5 8 0/5 189 (126–297) Treatment/ Tumor Time to1000 Drug T/C Free on mg days T-C Log Cage Route % day 21 (range) (days)Kill Comments 1 No Rx — 0/5 11 (11–16) — — — 5 14a (PO) 7.3 0/5 23(21–35) 12 1.9 active (++) 6 14a (PO) 40 0/5 15.5 (13–18.5) 4.5 0.7active (+) 7 14a (PO) 74 0/5 13 (11.5–22) 2 0.3 inactive (−−) 8 XK469(IV) 11 0/5 20 (18.5–23) 9 1.4 active (++) Mice: BDF1 Males; DOB: Jun.14, 1999; DOA: Jul. 27, 1999; Source: NIH: CRL-Raleigh; Ave. Wt. = 22.8g Tumor: Pancreatic Adenocarcinoma P03/215; DOT: Aug. 2, 1999; Time to1,000 mg = 11 days; Td = 1.9 days Preparation: Compound 14a: solid lightyellow powder + 3% EtOH + 1% Tween-80 + dH₂O → suspension; pH = 5.5; 0.2mL/mouse/inj. XK469: (NIH:D697887, Lot#KS18-140-1): 90 mg/kg liquidstock diluted to 60 mg/kg with dH₂O→solution; pH = 8.0→6.5 with 1.0 NHCl; 0.2 mL/mouse/inj.

TABLE 2 Evaluation of Compound 14b Against Early Stage Pancreatic DuctalAdenocarcinoma #03 Mean Drug Total Body Wt. % Deaths Median Tumor Rx/Dosage Loss Body Wt. Day of Wt. (day of Burden in mg Cage Route Schedmg/kg (g/mouse) Loss Loss Nadir death) on d18 (Range) 1 NoRx — — 0 0 5 —1713 (1295–2486) 2 XK469 (IV) QD3– 300 −3.2 15 8 0/5 64 (32–126) 6, 10 314b (PO) BID3– 2,300 −2.0 9 8 0/5 671 (203–748) 7 4 14b (PO) BID 480−0.8 4 5 0/5 1266 (895–1600) 3, 4 5 14b (PO) BID 3 108 +0.4 0 5 0/5 1312(756–1387) Tumor Time in days Growth Log Rx/ T/C Free on to 1000 mgDelay Cell Activity Cage Route % d 154 (range) (days) Kill Rating 1 NoRx— 0/5 13 (11–14) — 2 XK469 (IV) 4 1/5 41.1 (36.6–44.3) 28.1 3.3 ++++Highly Active 3 14b (PO) 39 0/5 21 (19.5–38) 7.0 0.8 + Modestly Active 414b (PO) 74 0/5 15 (14.5–15) 2.0 0.2 − Inactive 5 14b (PO) 77 0/5 15.7(13.8–19.8) 2.7 0.3 − Inactive Mice: BD₁ Female; Source: CRL-Raleigh;DOB: Jan. 24, 2000; DOA: Feb. 29, 2000; Av. Wts. = 21.6 g/mouse Tumor:PO3/229; DOT: Apr. 14, 2000; Td = 2.6 days Preparation: XK469 (Racemic,lot KS 18-140-1, NCI): White powder + 1% NaHCO₃ + PBS Solution; pHadjusted to 7.0 with HCl; 0.2 mL/mouse/inj; Compound 14b: white powder +5% EtOH, 3% POE + PBS Suspension; pH = 7; 0.2 mL/mouse/inj.

TABLE 3 Evaluation of Compound 14c Against Early Stage MammaryAdenocarcinoma 17/ADR Total % Body Median Tumor Rx Cpd # of dose Wt LossDay of Drug Mass on Day 9 Cage (Route) Inj. mg/kg at Nadir Nadir Deaths(Range) 1 No Rx 0 0 +1.4% 7 — 1201 (1044–2220) 2 Adriamycin 2 15 −1.4% 70/5 1086 (863–1506) 4 XK469 (IV) 6 336 −7.1% 8 0/5 108 (63–270) 5 14c(PO) 6 870 −5.8% 9 0/5 243 (126–385) 6 14c (PO) 6 540 +1.4% 9 0/5 369(234–466) 7 14c (PO) 6 334.8 +0.0% 9 0/5 368 (239–878) 8 14c (PO) 6538.8 −1.4% 11 0/5 660 (271–835) % Growth Tumor Rx Cpd T/C Delay LogFree Activity Cage (Route) mass in Days Kill day-21 Rating 1 No Rx — — —0/5 — 2 Adriamycin 90% 0 none 0/5 −− 4 XK469 (IV)  9% 15.5 4.2 0/5 ++++5 14c (PO) 20% 5.5 1.5 0/5 ++ 6 14c (PO) 31% 5.0 1.4 0/5 ++ 7 14c (PO)31% 3.5 1.0 0/5 + 8 14c (PO) 55% 3.3 0.9 0/5 + Mice = C3H/He femalesSource NCI CRL-Kingston DOB = Dec. 13, 1999 DOA = Jan. 25, 2000 Avg. Wt= 27.6 gm Tumor = Mammary Adenocarcinoma-17/Adr, a p-glycoproteinpositive multi-drug resistant tumor/pass-194 DOT = Mar. 20, 2000 Td 1.1days File = 2586

TABLE 4 Evaluation of Compounds 11b, 14e, and XK469 Against Early StagePancreatic Ductal Adenocarcinoma 03 in female BDF1 mice. Total % BodyMedian Tumor Rx # of dose Wt Loss Day of Drug Mass on Day 14 Cage(Route) Inj. mg/kg at Nadir Nadir Deaths (Range) 1 No Rx 0 0 +12% 10 —1513 (681–2149) 2 14e (PO) 14 1680 +4.3 9 0/5 126 (63–264) 3 14e (PO) 14840 +3.3 10 0/5 234 (75–333) 4 14e (PO) 14 420 0 9 0/5 567 (446–1200) 5XK469 (IV) 7 399 −6.7% 8 0/5 63 (0–214) 6 XK469 (IV) 7 266 −6.7% 5 0/5126 (0–234) 14 11b (IV) 7 336 −8.9% 11 0/5 0 (0–126) % Growth Tumor RxT/C Delay Log Free Activity Cage (Route) mass in Days Kill day-37 Rating1 No Rx — — — 0/5 — 2 14e (PO) 8.3%  16.5 2.5 0/5 +++ 3 14e (PO) 15%14.5 2.2 0/5 +++ 4 14e (PO) 37% 3.5 0.5 0/5 ± 5 XK469 (IV) 4.1%  11.51.7 0/5 ++ 6 XK469 (IV) 8.3%  9.5 1.4 0/5 ++ 14 11b (IV)  0% 17.5 2.60/5 +++ Mice = BDF1 females Source NCI-Raleigh DOB = Mar. 27, 2000 DOA =May 9, 2000 Av. Wt. = 18.2 gm Tumor = Pancreatic Ductal Adenocarcinoma03/ pass-231 DOT = May 19, 2000 Td = 2.0 days File = 2606 This tumor ishighly sensitive to Taxol (++++ activity rating). It is nicely sensitiveto Adriamycin (+++ activity). It is moderately sensitive to VP-16,Cytoxan, CisDDPt (++ activity rating). It is modestly responsive to 5-FU(+ activity). It is insensitive to Vinblastine. Preparation: XK469 (R):white solid: 1% bicarb + PBS gave a solution, pH = 7.5; 0.2 mL/inj IV,QD 3–9; Compound 14e: white solid + 6% ethanol + 3% POE80 + dH2O gave asuspension, pH = 4.5; 0.2 mL/inj PO BID days 3–9; and Compound 11b:white solid + 1% bicarb + PBS gave a solution, pH = 7.5; 0.2 mL/inj IV,QD 3–9

TABLE 5 Evaluation of Compound 14f Against Early Stage Pancreatic DuctalAdenocarcinoma #03 Mean Drug Median Treatment Body Day of Death TumorCompound Total Wt. Loss Percent Wt. (day Burden in (Drug Dosage in BodyLoss of mg on d17 Cage Route) Schedule mg/kg g/mouse Wt. Loss Nadirdeath) (range) 1 No Rx — — +0.8 +3.5 11 — 1202 (235–1666) 2 XK469 (R) qd3–10 360 −1.6 −1.6 11 0/5 256 (216–554) (IV) 3 14f (IV- qd 3–5, 780 +0.0+0.0 11 0/5 126 (63–322) SC) 8–11 BID 6, 7 4 14f (IV- ↓ 390 +0.8 +3.5 110/5 600 (108–726) SC) 5 14f (IV) qd 3, 4 30 +1.6 +7.1 11 0/5 1420(446–1574) Treatment Time to Compound Tumor 1000 mg Log (Drug T/C Freeon in days T-C Cell Cage Route) % d35 (range) (days) Kill Comments 1 NoRx — 0/5 16 (14–22) — — — 2 XK469 (R) 21 0/5 27 (20–30) 11.0 1.84 Active(IV) (++) 3 14f (IV- 10 0/5 26 (24–31) 10.0 1.67 Active SC) (++) 4 14f(IV- 50 0/5 19.5 (18–26) 3.5 0.58 Inactive SC) (−−) 5 14f (IV) >100 0/516 (14–23) 0.0 0.0 Inactive (−−) Mice: C₅₇ females Source: NCI FrederickDOB: Oct. 22, 2001 DOA: Dec. 4, 2001 Av. Wt. = 22 g/mouse Tumor: Panc03/124 DOT: Feb. 1, 2002 Td = 1.8 days Preparation: XK469 (R): 99.4% (R)liquid stock + 0.5% NaHCO₃ + PBS → solution (pH = 7.5); 0.2mL/mouse/inj; Compound 14f: off white solid + dH₂O → solution (pH =5.5), 0.2 mL/mouse/inj.

TABLE 6 Evaluation of Compounds 14f (R) and 14f (S) Against Early StageHuman Melanoma LOX in Balb/c females Mean Drug Cpd Body Percent Day ofDeath Median (Config) Total Wt. Loss Body Wt. (day Tumor (Admin Dosagein Wt. Loss of Burden in mg Cage Route) Schedule mg/kg g/mouse LossNadir death) on d 9 (Range) 1 No Rx — — +1.2 +5.9 7 — 1394 (1057–1674) 214f (R) qd 1–6 700 −2.8 13.5 13 0/5 651 (63–1114) (IV) BID 7 3 14f (S)qd 1–6 700 +0.4 2.0 8 0/5 994 (734–1200) (IV) BID 7 4 XK469 (R) qd 1–7175 −1.6 8.0 7 0/5 467 (234–1067) (IV) Time to Cpd(Config) Tumor 1000 mgLog (Admin T/C Free on days T-C Cell Cage Route) % d 18 (range) (days)Kill Comments 1 No Rx — 0/5 8.0 (8.0–9.0) — — Inactive (−−) 2 14f (R) 470/5 11.0 (8.5–23.5) 3.0 0.8 Active (IV) (+) 3 14f (S) 71 0/5 9.0(8.0–10.0) 1.0 0.3 Inactive (IV) (−−) 4 XK469 (R) 34 0/5 11.3 (9.0–13.0)3.3 0.8 Active (IV) (+) Mice: Balb/c SCID Source: NCI- Frederick DOB:Nov. 26, 2001–Dec. 3, 2001 DOA: Jan. 8, 2002 Ave wt: 20.3 g/mouse Tumor:Human Melanoma LOX/39S DOT: Apr. 8, 2002 Td: 1.2 days Preparation: XK469(R): (98.4 enan. excess); 0.5% NaHCO₃ + PBS → solution (pH = 9 + 1N HCl−> pH = 7); 0.2 mL/mouse/inj.; Compound 14f (R): white solid + dH₂O →solution (pH = 5.5); 0.2 mL/mouse/inj.; and Compound 14f (S): whitesolid + dH₂O → solution (pH = 5.5); 0.2 mL/mouse/inj.

TABLE 7 Evaluation of Compound 14g Racemic, XK469 (R), and 11c (R)Against Early Stage Mammary Adenocarcinoma 16/C Mean Drug Median BodyPercent Day of Death Tumor Total Wt. Loss Body Wt. (day Burden in DrugDosage in Weight Loss of mg on d 9 Cg Treatment Route Schedule mg/kgg/mouse Loss Nadir death) (range) 1 No Rx — — — +0.8 0.0 4 — 1656(1418–2526) 2 14g IV BID 1–5 600 −2.3 −11.0 4 0/6 230 (0–728) (Racemic)3 XK469 (R) IV qd 1–5 250 −4.4 −21.2 7 0/5 63 (0–365) 4 11c (R) IV qd1–5 240 −6.0 −29.4 9 1/5 0 (all zeros) (10) Time to Tumor 1,000 mg LogT/C Free on in days T-C Cell Cg Treatment % d 161 (range) (days) KillComments 1 No Rx — 0/5 8 (7–8) — — — 2 14g 14 1/6 11.5 (9.5–13) 3.5 0.9Active (Racemic) (+) 3 XK469 (R) 4 0/5 14.5 (12.5–19) 6.5 1.6 TOXIC 411c (R) 0 0/5 15.2 (13–17) 7.2 1.8 TOXIC Mice: C₃H females; Source:CRL - Kingston; DOB: Mar. 18, 2002; DOA: Apr. 22, 2002; Av. Wt. = 20.6g/mouse Tumor: Mammary 16/C/204; DOT: May 6, 2002; Td = 1.2 daysPreparation Compound 14g Racemic: white solid + dH₂O + heat → solution(pH = 7); 0.2 ml/mouse/inj. Compound XK469 (R): white solid + 0.5%NaHCO₃ (by volume) + dH₂O → solution (pH = 10→7 w/1 N HCl); 0.2ml/mouse/inj. Compound 11c (R): white solid + 0.5% NaHCO₃ (by volume) +dH₂O → solution; (pH = 10→7 w/1 N HCl); 0.2 ml/mouse/inj.

TABLE 8 Evaluation of Compounds 14f (R), 11c (R), and XK469 (R) AgainstEarly State Mammary Adenocarcinoma 16/c. Mean Drug Body Percent Day ofDeath Median Tumor Total Wt. Loss Body Wt. (day Burden in mg Drug Dosagein Weight Loss of on day 7 Cg Treatment Route Schedule mg/kg g/mouseLoss Nadir death) (range) 1 NoRx — — — +1.6 +5.8 7 — 1820 (1286–2736) 211c (R) IV Q2Dx8 480 −1.2 −4.3 14 0/5 0 (all zero) 3 XK469 (R) IV Q2Dx8480 −2.0 −7.4 18 0/5 0 (all zero) 4 14f (R) IV d1, 3–5, 1610 −0.8 −3.014 0/5 0 (0–151) 7, 9, 11, 13, 15 5 14f (R) IV d1, 3–7, 9 665 −0.8 −2.95 0/5 260 (0–523) Time to Tumor 1000 mg Log T/C Free on in days T-C CellCg Treatment % d28 (range) (days) Kill Comments 1 NoRx — 0/5 6 (all d6)— — — 2 11c (R) 0 0/5 22 (20–24) 16 4.8 Active (++++) 3 XK469 (R) 0 0/524 (19–26) 18 5.4 Active (++++) 4 14f (R) 0 0/5 20 (16.5–22) 14 4.2Active (++++) 5 14f (R) 14 0/5 12 (10–16.5) 6 1.8 Active (++) Mice:C₃H/HeN MTV(−) females; Source: NCI-Frederick; DOB: Aug. 19, 2002; DOA:Oct. 1, 2002; Av. Wt. = 27.6 g/mouse; Tumor: Mam16/C/73; DOT: Nov. 4,2002; Td = 1.0 day Preparation: Compound 11c (R): white solid + 3%EtOH + 1% POE + 0.25% NaHCO₃ (by volume) + dH₂O → solution (pH = 9 → 7w/1N HCl); 0.2 ml/mouse/inj. IV. Compound XK469 (R): white solid + 3%EtOH + 1% POE + 0.25% NaHCO₃ (by volume) + dH₂O → solution (pH = 7.5);0.2 ml/mouse/inj. IV. Compound 14f (R): white solid + dH₂O → solution(pH = 5); 0.2 ml/mouse/inj. IV.

TABLE 9 Evaluation of Compounds 14g (R) and 11c (R) Against Early StagePancreatic Ductal Adenocarcinoma 03. Mean Body Percent Day of DrugMedian Tumor Total Wt. Loss Body Wt. Death Burden in Drug Dosage inWeight Loss (day of mg on d14 Cg Treatment Route Schedule mg/kg g/mouseLoss Nadir death) (range) 1 NoRx — — — +2.0 +10.0 9 — 1004 (550–1093) 214g (R) IP BID3–5 450 −4.4 −23.4 9 1/5 0 (0–63) (10) 3 14g (R) IP BID3–7450 −1.2 −6.7 9 0/5 126 (100–252) 4 11c (R) IP Qd3–7 260 −3.2 −16.7 101/5 126 (0–298) (14) 5 11c (R) IP Qd3–7 157.5 −0.0 −0.0 9 0/5 260(75–351) Time to Tumor 1000 mg Log T/C Free on in days T-C Cell CgTreatment % d31 (range) (days) Kill Comments 1 NoRx — 0/5 14 (13–18) — —— 2 14g (R) 0 0/5 24.75 (23–27) 10.75 1.52 LD20 3 14g (R) 12.6 0/5 26(20–27) 12 1.72 Active (++) 4 11c (R) 12.6 0/5 24.5 (19–26) 10.5 1.5LD20 5 11c (R) 26 0/5 25 (22.5–26) 11 1.58 Active (++) Mice: C₅₇females; Source: NCI-Frederick; DOB: Jul 29, 2002; DOA: Sep. 17, 2002;Av. Wt. = 18.5 g/mouse; Tumor: Panc 03/135; DOT: Sep. 27, 2002; Td = 2.1days Preparation: Compound 14g (R): white solid + 3% EtOH + 1% POE +dH₂O → solution (pH = 7); 0.5 ml/mouse/inj. IP. Compound 11c (R): whitesolid + 3% EtOH + 1% POE + 0.25% NaHCO₃ (by volume) + dH₂O → solution(pH = 9.5 → 7 w/1N HCl); 0.5 ml/mouse/inj. IP.

TABLE 10 Evaluation of Compounds 14h (R), 14i (R), 11c (R), and XK469(R), Against Early Stage Pancreatic Ductal Adenocarcinoma 03. Mean BodyPercent Day of Drug Median Tumor Total Wt. Loss Body Wt. Death BurdenDrug Dosage in Weight Loss (day of in mg on Cage Treatment RouteSchedule mg/kg g/mouse Loss Nadir death) d17 (range) 1 No Rx — — — +2.4+10.0 10 — 1838 (691–2457) 2 14i (R) IP d 3 135 −1.6 −6.7 7 0/5 189(0–615) 3 ↓ ↓ ↓ 80 −0.5 −2.0 4 1/5 675 (108–1302) (d4) 4 ↓ IP d3 455−0.8 −3.4 7 0/5 151 (126–196) IV Q2d: 5–15 5 XK469 (R) SC Qd3–5 240 −4.0−16.7 9 1/4 171 (63–529) (d10) 6 ↓ IP d3, 5, 11, 320 −2.8 −11.6 8 0/5 88(0–352) 13 7 ↓ ↓ Q2d: 3–15 350 −0.8 −3.0 8 0/5 235 (0–428) 8 14h (R) IPd 3 615 −2.8 −11.6 9 0/5 63 (0–171) SC d5, 7, 11, 13, 15 9 ↓ IP d3, 5,7, 480 −3.2 −13.3 10 0/5 108 (0–171) 11, 13, 15 10 ↓ ↓ Q2d: 3–15 350−1.6 −6.6 8 0/5 304 (63–427) 11 11c (R) IP d3, 5, 11, 400 −4.4 −18.0 90/5 0 (0–108) 13, 15 12 ↓ ↓ Q2d: 3–15 350 −0.8 −3.2 8 0/5 63 (0–309)Time to Tumor 1000 mg Log T/C Free on in days T-C Cell Cage Treatment %148 (range) (days) Kill Comments 1 No Rx — 0/5 15 (12–19) — — — 2 14i(R) 10 0/5 22.5 (19–26) 7.5 1.1 Active (+) 3 ↓ 37 0/5 20 (16–29.5) 5 0.7Active (+) 4 ↓ 8 0/5 26 (23–30) 11 1.6 Active (++) 5 XK469 (R) 9 0/5 26(19–29.5) 11 1.6 Active (+) 6 ↓ 5 0/5 29 (25–29) 14 2.0 Active (+++) 7 ↓13 0/5 30 (26–31) 15 2.2 Active (+++) 8 14h (R) 3 0/5 28 (28–40) 13 1.9Inactive (++) 9 ↓ 6 0/5 27 (26–44) 12 1.7 Active (++) 10 ↓ 16.5 0/5 22(21.5–28) 7 1.0 Active (+) 11 11c (R) 0 1/5 38 (36–50) 23 3.3 Active(++++) 12 ↓ 3 0/5 25 (22.5–30) 10 1.4 Active (++) Mice: BDF₁ males;Source: CRL-Raleigh; DOB: Aug. 26, 2002; DOA: Oct. 8, 2002; Av. Wt. =23.5 g/mouse; Tumor: PO3/135; DOT: Oct. 18, 2002; Td = 2.1 daysPreparation: Compound 14h (R): white solid + 3% EtOH + 1% POE + 0.25%NaHCO₃ + saline → suspension (pH = 8.0); 0.5 ml/mouse/inj, IP; 0.2ml/mouse/inj, SC. Compound 14i (R): white solid + 3% EtOH + 1% POE +0.25% NaHCO₃ + saline → solution (pH = 8.0); 0.5 ml/mouse/inj, IP; 0.2ml/mouse/inj, IV. Compound XK469 (R): white solid + 3% EtOH + 1% POE +0.5% NaHCO₃ + saline → solution (pH = 9 → 7 with 1N HCl); 0.2ml/mouse/inj, SC; 0.5 ml/mouse/inj, IP. Compound 11c (R): white solid +3% EtOH + 1% POE + 0.25% NaHCO₃ + saline → solution (pH = 9 → 7 with 1NHCl); 0.5 ml/mouse/inj, IP.

1. A compound of formula (I):

wherein A is CH; X is F, Cl, or Br; Y is hydrogen, hydroxy, or(C₁–C₇)alkoxy; and Z is an amino acid, or heterocycle; or apharmaceutically acceptable salt thereof.
 2. The compound of claim 1,wherein Y is H.
 3. The compound of claim 1, wherein Y is —OH.
 4. Thecompound of claim 1, wherein Y is —OMe.
 5. The compound of any of claims1 to 4 wherein X is —Cl.
 6. The compound of any of claims 1 to 4 whereinX is —Br.
 7. The compound of any of claims 1 to 6 wherein Z is an aminoacid.
 8. The compound of any of claims 1 to 6 wherein Z is—NH—(CH₂)₂—SO₃H.
 9. The compound of any of claims 1 to 6 wherein Z is—NH—CH₂—CO₂H.
 10. The compound of any of claims 1 to 6 wherein Z is—NH—CH(CH₃)—CO₂H.
 11. The compound of any of claims 1 to 6 wherein Z isa nitrogen linked pyrrolidino, piperidino, morpholino,1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
 12. Acompound of formula (I):

wherein A is CH; X is F, Cl, or Br; Y is hydroxy, or (C₁–C₇)alkoxy; andZ is an —NR_(a)R_(b); where R_(a) and R_(b) is independently hydrogen,(C₁–C₇)alkyl, (C₁–C₇)alkanoyl, aryl, aryl(C₁–C₇)alkyl, or where R_(a)and R_(b) together with the nitrogen to which they are attached are apyrrolidino, piperidino, morpholino, 1,3-benzodiazepino,1,4-benzodiazepino, or 1,5-benzodiazepino; or a pharmaceuticallyacceptable salt thereof.
 13. The compound of claim 12, wherein Y is —OH.14. The compound of claim 12, wherein Y is —OMe.
 15. The compound of anyof claims 12 to 14 wherein X is —Cl.
 16. The compound of any of claims12 to 14 wherein X is —Br.
 17. The compound of any of claims 12 to 16wherein Z is —NR_(a)R_(b).
 18. The compound of any of claims 12 to 16wherein Z is —NH₂.
 19. The compound of any of claims 12 to 16 wherein Zis —NHCH₃.
 20. The compound of any of claims 12 to 16 wherein Z is anitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or1,5-benzodiazepino.
 21. A compound of formula (I):

wherein A is CH; X is F, Cl, or Br; Y is hydrogen, hydroxy, or(C₁–C₇)alkoxy; and Z is —NR_(a)R_(b); R_(a) and R_(b) are eachindependently hydrogen, (C₁–C₇)alkyl, (C₁–C₇)alkanoyl, aryl,aryl(C₁–C₇)alkyl, or where R_(a) and R_(b) together with the nitrogen towhich they are attached are a pyrrolidino, piperidino, morpholino,1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino; or apharmaceutically acceptable salt thereof.
 22. The compound of claim 21wherein R_(a) and R_(b) are each independently (C₁–C₇)alkanoyl, aryl,aryl(C₁–C₇)alkyl, or where R_(a) and R_(b) together with the nitrogen towhich they are attached are a pyrrolidino, piperidino, morpholino,1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
 23. Thecompound of claim 21 or 22 wherein Y is H.
 24. The compound of claim 21or 22 wherein Y is —OH.
 25. The compound of claim 21 or 22 wherein Y is—OMe.
 26. The compound of any of claims 21 to 25 wherein X is —Cl. 27.The compound of any of claims 21 to 25 wherein X is —Br.
 28. Thecompound of any of claims 21 to 27 wherein Z is —NR_(a)R_(b).
 29. Thecompound of any of claims 21 to 27 wherein Z is a nitrogen linkedpyrrolidino, piperidino, or morpholino.
 30. The compound of any ofclaims 21 to 27 wherein Z is a nitrogen linked 1,3-benzodiazepino,1,4-benzodiazepino, or 1,5-benzodiazepino.
 31. The compound2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy}propionmethylamide;2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy}propiondimethylamide;2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy}propionylamino ethanesulfonicacid; {2-{4-(7-Bromo-2-quinolin-2-yloxy)phenoxy}propionylamino}eceticacid; (R) (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy)propionylaminoethanesulfonic acid; (R){2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]propionylamino}acetic acid; orpharmaceutically acceptable salts thereof.
 32. The compound of any ofclaims 1 to 30 or 31 which is the (R) enantiomer.
 33. The compound ofany of claims 1 to 30 or 31 which is the (S) enantiomer.
 34. Thecompound of any of claims 1 to 30 or 31 to 33, wherein the compound isisolated and purified.
 35. The compound of claim 34, wherein thecompound is a solid.
 36. The compound of claim 34, wherein the compoundis a crystalline solid.
 37. A pharmaceutical composition comprising acompound any one of claims 1 to 30 or 31 to 36 and a pharmaceuticallyacceptable diluent or carrier.
 38. The pharmaceutical composition ofclaim 37, wherein the pharmaceutical composition is formulated as a unitdosage form.
 39. The pharmaceutical composition of claim 38, wherein theunit dosage form is formulated for oral administration.
 40. Thepharmaceutical composition of claim 38, wherein the unit dosage form isformulated for administration by injection.